



(11)

EP 2 850 097 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
25.07.2018 Bulletin 2018/30

(21) Application number: **13713371.6**

(22) Date of filing: **15.03.2013**

(51) Int Cl.:
C07K 14/435 ^(2006.01)

(86) International application number:
PCT/EP2013/055327

(87) International publication number:
WO 2013/167298 (14.11.2013 Gazette 2013/46)

(54) **ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAME**
ENTZÜNDUNGSHEMMENDE PEPTIDE UND ZUSAMMENSETZUNG DAMIT
PEPTIDES ANTI-INFLAMMATOIRES ET COMPOSITION COMPRENANT CEUX-CI

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **11.05.2012 KR 20120050529**
11.05.2012 KR 20120050533
02.07.2012 KR 20120071989
19.09.2012 KR 20120104144
19.09.2012 KR 20120104207

(43) Date of publication of application:
25.03.2015 Bulletin 2015/13

(73) Proprietors:
• **KAEL-GemVax Co.,Ltd**
Gyeonggi-do 463-440 (KR)
• **Kim, Sang Jae**
Gyeonggi-do 463-440 (KR)

(72) Inventors:
• **KIM, Sang, Jae**
Seongnam-si
Gyeonggi-do 463-440 (KR)
• **KIM, Kyung, Hee**
Seongnam-si
Gyeonggi-do 463-440 (KR)
• **LEE, Kyu-Yong**
Seoul 133-070 (KR)
• **KOH, Seong-Ho**
Seoul 133-070 (KR)
• **PARK, Hyun-Hee**
Seoul 133-070 (KR)
• **HUH, Sung, Jin**
Seongnam-si
Gyeonggi-do 463-440 (KR)

• **LEE, Woo, Jin**
Seongnam-si
Gyeonggi-do 463-440 (KR)
• **KIM, Bum, Joon**
Seoul 110-744 (KR)

(74) Representative: **Inspicos P/S**
Kogle Allé 2
2970 Hørsholm (DK)

(56) References cited:
WO-A1-00/02581 WO-A1-2011/101173
US-A1- 2007 190 561

• **DATABASE Geneseq [Online] 5 May 2000**
(2000-05-05), "Telomerase peptide #251.",
XP002756538, retrieved from EBI accession no.
GSP:AA Y86836 Database accession no.
AA Y86836
• **DATABASE Geneseq [Online] 5 May 2000**
(2000-05-05), "Telomerase peptide #267.",
XP002756539, retrieved from EBI accession no.
GSP:AA Y86852 Database accession no.
AA Y86852
• **MARTINEZ PAULA ET AL: "Telomeric and**
extra-telomeric roles for telomerase and the
telomere-binding proteins", NATURE REVIEWS
CANCER,, vol. 11, no. 3, 1 March 2011
(2011-03-01), pages 161-176, XP002696628,
• **DATABASE Geneseq [Online] 5 May 2000**
(2000-05-05), "Telomerase peptide #251.",
XP002756538, retrieved from EBI accession no.
GSP:AA Y86836 Database accession no.
AA Y86836

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 850 097 B1

- DATABASE Geneseq [Online] 5 May 2000 (2000-05-05), "Telomerase peptide #267.", XP002756539, retrieved from EBI accession no. GSP:AA Y86852 Database accession no. AAY86852

Description

FIELD OF THE INVENTION

5 **[0001]** The present invention relates to anti-inflammatory peptides and compositions comprising the same.

BACKGROUND OF THE INVENTION

10 **[0002]** Inflammation is a type of biological defense as a means of protecting the body from damage of biological tissues that could be caused by external physical stimuli, chemical stimuli such as exposure to various allergens, or invasion of microorganisms including bacteria, fungi and viruses.

15 **[0003]** The Cyclooxygenase(COX) pathway or Lipoxygenase(LOX) Pathway can be used for signaling inflammation, which produces prostaglandin, thromboxane, etc. Once the inflammatory signal is delivered, one of many changes that happen in the body is the expansion of the blood vessel for increased blood supply around the inflammation to concentrate blood cells such as neutrophils required for the inflammatory response. However, inflammatory diseases can result if an abnormal biological defense response occurs excessively. To prevent from this, drugs that suppress excessive inflammatory response by repressing enzymes used in inflammatory signaling pathway (for example, COX-1, COX-2, 5-LOX, 12-LOX etc.) are under development.

20 **[0004]** According to response time, inflammation is categorized as acute inflammation (immediate response, non-specific response, several days to several weeks), chronic inflammation (delayed response, specific response, several weeks or more), subacute inflammation (a middle stage in between acute inflammation and chronic inflammation, characteristics of mixed product of mononuclear and polymorphonuclear).

25 **[0005]** Also, aside from peptide factors, factors such as prostaglandin, leukotriene, lipid factors including platelet activating factor(PAF), synthetic enzyme of inflammation factor, free radical such as NO(nitric oxide), many kinds of cell adhesion molecule, immune system, and coagulation factors can cause inflammation.

30 **[0006]** Once a cell is damaged due to the known causative agents of inflammation such as external biological factors (microbes, viruses, parasites), physical factors (mechanical stimuli, heat, radiation, electricity), and chemical factors, histamine and kinin are released. The released histamine and kinin will result in angiectasis, increased capillary permeability and concentration of macrophages at the inflammation site, and it causes increased blood flow rate, edema, immunocyte and antibody migration, pain and heat generation.

35 **[0007]** Currently used treatments for inflammation are synthetic drugs such as ibuprofen, antihistamines, steroids, cortisone, immunosuppressive agents, and immune agonist; those which only temporarily alleviate inflammation. These drugs do not fundamentally cure inflammation, and they have side effects such as hypersensitivity reaction, and deterioration of immune system,

40 Therefore, for effective alleviation of inflammation, research is carried out to develop a substance that inhibits expression of the above mentioned inflammatory proteins. However, problems have arisen in anti-inflammation substances that had been developed previously. Diverse categories of anti-inflammatory drugs including Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Steroidal Anti-inflammatory Drugs (SAIDs) have been developed; but not only do these drugs often bear side effects upon use, they also do not fundamentally cure the inflammation. Thus, there is a current need for anti-inflammatory drugs that both physically and economically feasible. As one example, in acute or chronic inflammations such as chronic rheumatoid arthritis, not only do non-steroidal anti-inflammatory drugs suppress COX-2 enzyme activity, they are also known to suppress COX-1 activity, causing side effects such as gastrointestinal disorders.

45 **[0008]** The present invention was completed as the present inventors have found that peptides derived from telomerase can have anti-inflammatory properties.

50 **[0009]** Therefore the objective of this invention is to provide a novel peptide.

55 **[0010]** Another objective of present invention is to provide the polynucleotide that codes the novel peptide.

60 **[0011]** Another objective of present invention is to provide a peptide that has anti-inflammatory activity.

65 **[0012]** Another objective of present invention is to provide an anti-inflammatory composition that uses this peptide as an active ingredient.

70 **[0013]** Another objective of present invention is to provide a cosmetic composition that uses this peptide as an active ingredient.

75 **[0014]** Another objective of present invention is to provide a pharmaceutical composition that uses this peptide as an active ingredient.

80 **[0015]** WO 00/02581 discloses the peptides having the sequences #251 and # 267, which have the amino acid sequences REARPALLT and EARPALLTS, respectively. These peptides are suggested as immunogens for use in cancer vaccination.

85 **[0016]** WO 2011/101173 discloses peptides derived from telomerase, which have lengths of at least 8 amino acid residues.

[0017] US 2007/190561 discloses a peptide comprising current SEQ ID NO:2 and suggests the use thereof for treatment of cancers, other diseases of cell proliferation, immunological disorders and infertility (or fertility).

[0018] Martinez P et al., 2011, Nature Reviews Cancer 11(3), 161-176, discloses discusses the role of telomeric proteins in cancer and ageing through modulating telomere length and protection, as well as regulating gene expression by binding to non-telomeric sites.

SUMMARY OF THE INVENTION

[0019] In one embodiment of the present invention, a peptide with anti-inflammatory activity, wherein the peptide is selected from the group consisting of SEQ ID NO:116, 117 and 118 is provided.

[0020] In another embodiment, the above-mentioned peptide originates from human telomerase.

[0021] In one embodiment of the present invention, a polynucleotide encoding a peptide with anti-inflammatory activity, wherein the peptide is selected from the group consisting of SEQ ID NO:116, 117 and 118 is provided.

[0022] In one embodiment of the present invention, anti-inflammatory composition comprising a peptide as active ingredient, wherein the peptide is selected from the group consisting of SEQ ID NO: 116, 117, and 118, is provided.

[0023] In another embodiment of the composition, the above-mentioned composition is for treatment or prophylaxis of inflammatory disease.

[0024] In another embodiment of the composition, the above-mentioned composition is a cosmetic composition for improving or preventing skin inflammation.

[0025] In another embodiment of the composition, the above-mentioned composition is a pharmaceutical composition for treatment or prophylaxis of inflammatory diseases.

[0026] In another embodiment of the composition, the above-mentioned composition is a food composition for treatment or prophylaxis of inflammation.

[0027] In another embodiment of the composition, the above-mentioned inflammatory disease is characterized by selecting from the group consisting of (1) general or localized inflammatory disease (for example, allergies; immune-complex disease; hayfever; hypersensitive shock; endotoxin shock; cachexia, hyperthermia; granulomatosis; or sarcoidosis); (2) gastro-intestinal related diseases (for example, appendicitis; gastric ulcer; duodenal ulcer; peritonitis; pancreatitis; ulcerative, acute, or ischemic colitis; cholangitis; cholecystitis, steatorrhea, hepatitis, Crone's disease; or Whipple's Disease); (3) dermal related diseases (for example, psoriasis; burns; sunburns; dermatitis; Urticarial warts or wheal); (4) vascular related diseases (for example, angitis; vasculitis; endocarditis; arteritis; atherosclerosis; thrombophlebitis; pericarditis; congestive heart failure; myocarditis; myocardial ischemia; periarteritis nodosa; recurrent stenosis; Buerger's disease; or rheumatic fever); (5) respiratory diseases (for example, asthma; epiglottitis; bronchitis; emphysema; rhinitis; cystic fibrosis; interstitial pneumonitis; COPD(chronic obstructive pulmonary disease); adult respiratory distress syndrome; coniosis; alveolitis; bronchiolitis; pharyngitis; pleurisy; or sinusitis); (6) bone, joint, muscle and connective tissue related diseases (for example, eosinophilic granuloma; arthritis; arthralgia; osteomyelitis; dermatomyositis; fasciitis; Paget's disease; gout; periodontal disease; rheumatoid arthritis; myasthenia gravis; ankylosing spondylitis; or synovitis); (7) urogenital disorders (for example, epididymitis; vaginitis; prostatitis; or urethritis); (8) central or peripheral nervous system related diseases (for example, Alzheimer's disease; meningitis; encephalitis; multiple sclerosis; cerebral infarction; cerebral embolism; Guillain-Barre syndrome; neuritis; neuralgia; spinal cord injury; paralysis; or uveitis); (9) virus (for example, influenza; respiratory syncytial virus; HIV; hepatitis B; hepatitis C; or herpes virus), infectious disease (for example, Dengue fever; or septicemia), fungal infection (for example, candidiasis); or bacterial, parasitic, and similar microbial infection (for example, disseminated bacteremia; malaria; onchocerciasis; or amebiasis); (10) autoimmune disease (for example, thyroiditis; lupus; Goodpasture's syndrome; allograft rejection; graft versus host disease; or diabetes); and (11) cancer or tumor disease (for example, Hodgkin's disease).

[0028] The invention enables a method for treating or preventing inflammatory diseases by administering the anti-inflammatory composition.

[0029] In one embodiment of the present invention, a kit for prophylaxis or treatment of inflammatory diseases comprising: a peptide is selected from the group consisting of SEQ ID NO:116, 117 and 118 ; and instructions including at least one of administration dose, administration route, administration frequency, and indication of the peptide or composition, is provided.

INDUSTRIAL APPLICABILITY

[0030] According to the present invention, a peptide that has a sequence of SEQ ID NO: 116, 117, or 118 has outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical composition or as cosmetic composition, in turn, treating and preventing a variety of different types of inflammatory diseases.

REFERENCES

[0031]

- 5 KR2012-0130996A
- KR2012-0133661A
- KR2011-0060940A
- 10 US2011-0150873A1
- Bonaldi T et al., EMBO J, (22)5551-60, 2003
- 15 Yankner BA et al, Science (New York, N.Y.) [1990, 250(4978):279-282]
- Dahlgren KN et al, J. Biol. Chem. 277:32046-32053, 2002.

BRIEF DESCRIPTION OF THE DRAWINGS

[0032]

- FIG. 1 is a graph which shows the results of performing TNF- α ELISA with the culture of monocytes derived from PBMC. The monocytes were stimulated with LPS (10 ng/ml) for two hours, then reacted with each peptide, FITC, FITC-TAT, PEP 1-FITC and FITC-peptide for two hours. (** P < 0.01. Compared with the negative control (FITC and FITC-TAT).
- FIG. 2 is a graph which shows the results of performing luciferase analysis from transfecting HEK293/null and HEK293/TLR2 cell lines with NF- κ B luciferase, then reacting with lipoprotein (10 ng/ml) and FITC and FITC-PEP1(4 μ M), and incubating for 18 hours. Results of luciferase were obtained by correction using renilla. (** P < 0.01. compared to the negative control (No treat) and compared with lipoprotein treated sample.)
- FIG. 3 to FIG. 23 are results from screening TNF- α inhibition effects on monocytes.
- FIG. 24 to FIG. 46 are results from screening TNF- α inhibition effects on cell line THP-1.
- FIG. 47 represents viability of neural stem cell treated with 0, 2.5, 5.0, 10, 20 and 40 μ M of amyloid- β protein.
- FIG. 48 represents proliferation of neural stem cell treated with 0, 2.5, 5.0, 10, 20 and 40 μ M amyloid- β protein.
- FIG. 49 represents viability of neural stem cell treated with 0, 1, 10, 50, 100 and 200 μ M of PEP 1.
- FIG. 50 represents proliferation of neural stem cell treated with 0, 1, 10, 50, 100 and 200 μ M of PEP 1.
- FIG. 51 represents viability of neural stem cell treated with 1, 10, 50 and 100 μ M PEP 1; neural stem cells were damaged by 20 μ M of amyloid beta protein, and then cell viability was measured after treatment with different concentrations of PEP1. (Control groups were those untreated with amyloid beta protein and telomerase-based peptides).
- FIG. 52 represents toxicity of neural stem cell treated with 1, 10, 50 and 100 μ M PEP 1; neural stem cells were damaged by 20 μ M of amyloid beta protein, and then cell toxicity was measured after treatment with different concentrations of PEP1. (Control groups were those untreated with amyloid beta protein and telomerase-based peptides).
- FIG. 53 represents proliferation of neural stem cells treated with 1, 10, 50 and 100 μ M PEP 1; neural stem cells were damaged by 20 μ M of amyloid beta protein, and then cell proliferation was measured after treatment with different concentrations of PEP1. (Control groups were those untreated with amyloid beta protein and telomerase-based peptides).

FIG. 54 represents migration of neural stem cells treated with 1, 10, 50 and 100 μ M PEP 1; neural stem cells were damaged by 20 μ M of amyloid beta protein, and then cell migration was measured after treatment with different concentrations of PEP1. (Control groups were those untreated with amyloid beta protein and PEP1).

FIG. 55 represents apoptosis of neural stem cells treated with 1, 10, 50 and 100 μ M PEP 1; neural stem cells were damaged by 20 μ M of amyloid beta protein, and then cell apoptosis was measured after treatment with different concentrations of PEP1. (Control groups were those untreated with amyloid beta protein and telomerase-based peptides).

FIG. 56 represents ROS (Reactive Oxygen Species) inhibitory effect of PEP1 in neural stem cells damaged by amyloid beta peptide; neural stem cells were damaged by 20 μ M of amyloid beta protein, and then inhibition of ROS was measured after treatment with different concentrations of PEP1 (1, 10, 50 and 100 μ M). (Control groups were those untreated with amyloid beta protein and PEP1).

FIG. 57 represents the results of protein expression levels analyzed by (A) 2D-electrophoresis and (B) Antibody Array; neural stem cells were damaged by 20 μ M of amyloid beta protein, and then protein expression level was measured after treatment with different concentrations of PEP1 (1, 10 and 50 μ M). (Control groups were those untreated with amyloid beta protein and PEP1).

FIG. 58 represents the results of western blot showing the expression level of inflammation-related proteins: neural stem cells were damaged by 20 μ M of amyloid beta protein, and then cells were treated with different concentrations of PEP1 (1, 10 and 50 μ M).

FIG. 59 represents the inhibitory effect of PEP 1 on amyloid beta protein aggregation; (A) shows the reduced oligomerization of amyloid beta proteins when co-treated with 1 μ M amyloid beta protein and PEP 1 (0.1, 1 and 10 μ M). (B) shows the case when PEP-1 was treated on the amyloid- β protein that was already induced for aggregation.

FIG. 60 represents the effect of PI3K-inhibitor, LY294002 on the cell viability treated with PEP 1. The increased cell viability after treating with PEP 1 decreased when treated with LY294002.

FIG. 61 to FIG. 159 are the results from the western blot analysis of selected peptides showing accumulation of HMGB1 in the cell.

DETAILED DESCRIPTION OF THE INVENTION

[0033] Since the present invention can have adaptability for diverse transformation and examples of practical application, below is a more detailed description of the present invention. Nevertheless, this is no means to limit the form of practical application; it should be understood that the intention is to include the concept and the extent of technology in all of the transformation, equivalents to alternatives. In describing the present invention, if any detailed description about the prior art is considered to deteriorate the fundamental principles of the present invention, the description will be omitted.

[0034] A telomere is known as a repetitive sequence of genetic material at the ends of chromosomes that prevent chromosomes from damage or merging of other chromosomes. The length of a telomere is shortened at each cell division, and after a certain number of cell division, the telomere length is extremely shortened to the extent in which the cell stops dividing and dies. On the other hand, the elongation of telomeres is known to extend the life span of a cell. For an example, cancer cells excrete an enzyme called telomerase, which prevents shortening of telomeres, thus resulting in proliferation of cancer cells. The present invention was accomplished upon the discovery of telomerase-derived peptides with anti-inflammatory effects.

[0035] In one embodiment of the present invention, a peptide with anti-inflammatory activities is provided. The peptide is selected from the group consisting of SEQ ID NO:116, 117 and 118.

[0036] The peptides described in SEQ ID NO: 2 to SEQ ID NO: 179 are as the following table 1. SEQ ID NO: 180 lists the order of full length of human telomerase protein. SEQ ID NO: 1 lists the telomerase-derived peptide that consists of 16 amino acid sequence. The peptides that are mentioned in SEQ ID NO: 2 to SEQ ID NO: 179 are as the following table 1. SEQ ID NO: 180 lists the order of full length of human telomerase protein. SEQ ID NO: 1 lists the telomerase-derived peptide that consists of 16 amino acid sequence. Peptides in SEQ ID NO: 2 to SEQ ID NO: 77 are peptide including SEQ ID NO: 1. Peptides in SEQ ID NO: 78 to SEQ ID NO: 179 are fragments of peptide of SEQ ID NO: 1.

[0037] The "name" in Table 1 below was used for distinction of peptides. More than one peptide of the mentioned peptides in SEQ ID NO: 2 to SEQ ID NO: 179 comprise a "synthetic peptide", a synthesized peptide of selected areas

EP 2 850 097 B1

of the telomerase. In the present specification, the term "pep" herein relates to a peptide that has any one of the SEQ ID NO: 2 to SEQ ID NO: 179, or, a peptide comprising of amino acid sequence above 80% homology with above-mentioned sequences, or a peptide fragment of above-mentioned peptides.

Table 1

SEQ ID NO	NAME	POSITION IN TELOMERASE	SEQUENCE	LENGTH
1.	pep1	[611-626]	EARPALLTSRLRFIPK	16 aa
2.	pep-RIA-1	[610-626]	REARPALLTSRLRFIPK	17 aa
3.	pep-RIA-2	[609-626]	HREARPALLTSRLRFIPK	18 aa
4.	pep-RIA-3	[608-626]	QHREARPALLTSRLRFIPK	19 aa
5.	pep-RIA-4	[607-626]	RQHREARPALLTSRLRFIPK	20 aa
6.	pep-RIA-5	[606-626]	VRQHREARPALLTSRLRFIPK	21 aa
7.	pep-RIA-6	[605-626]	EVRQHREARPALLTSRLRFIPK	22 aa
8.	pep-RIA-7	[604-626]	AEVRQHREARPALLTSRLRFIPK	23 aa
9.	pep-RIA-8	[603-626]	EAEVRQHREARPALLTSRLRFIPK	24 aa
10.	pep-RIA-9	[602-626]	SEAEVRQHREARPALLTSRLRFIPK	25 aa
11.	pep-RIA-10	[601-626]	LSEAEVRQHREARPALLTSRLRFIPK	26 aa
12.	pep-RIA-11	[600-626]	ELSEAEVRQHREARPALLTSRLRFIPK	27 aa
13.	pep-RIA-12	[599-626]	RELSEAEVRQHREARPALLTSRLRFIPK	28 aa
14.	pep-RIA-13	[598-626]	LRELSEAEVRQHREARPALLTSRLRFIPK	29 aa
15.	pep-RIA-14	[597-626]	QLRELSEAEVRQHREARPALLTSRLRFIPK	30 aa
16.	pep-RIA-15	[610-627]	REARPALLTSRLRFIPKP	18 aa
17.	pep-RIA-16	[609-627]	HREARPALLTSRLRFIPKP	19 aa
18.	pep-RIA-17	[609-628]	HREARPALLTSRLRFIPKPD	20 aa
19.	pep-RIA-18	[610-628]	REARPALLTSRLRFIPKPD	19 aa
20.	pep-RIA-19	[608-627]	QHREARPALLTSRLRFIPKP	20 aa
21.	pep-RIA-20	[608-628]	QHREARPALLTSRLRFIPKPD	21 aa
22.	pep-RIA-21	[608-629]	QHREARPALLTSRLRFIPKPDG	22 aa
23.	pep-RIA-22	[609-629]	HREARPALLTSRLRFIPKPDG	21 aa
24.	pep-RIA-23	[610-629]	REARPALLTSRLRFIPKPDG	20 aa
25.	pep-RIA-24	[607-627]	RQHREARPALLTSRLRFIPKP	21 aa
26.	pep-RIA-25	[607-628]	RQHREARPALLTSRLRFIPKPD	22 aa
27.	pep-RIA-26	[607-629]	RQHREARPALLTSRLRFIPKPDG	23 aa
28.	pep-RIA-27	[607-630]	RQHREARPALLTSRLRFIPKPDGL	24 aa
29.	pep-RIA-28	[608-630]	QHREARPALLTSRLRFIPKPDGL	23 aa
30.	pep-RIA-29	[609-630]	HREARPALLTSRLRFIPKPDGL	22 aa
31.	pep-RIA-30	[610-630]	REARPALLTSRLRFIPKPDGL	21 aa
32.	pep-RIA-31	[606-627]	VRQHREARPALLTSRLRFIPKP	22 aa
33.	pep-RIA-32	[606-628]	VRQHREARPALLTSRLRFIPKPD	23 aa
34.	pep-RIA-33	[606-629]	VRQHREARPALLTSRLRFIPKPDG	24 aa
35.	pep-RIA-34	[606-630]	VRQHREARPALLTSRLRFIPKPDGL	25 aa

EP 2 850 097 B1

(continued)

	SEQ ID NO	NAME	POSITION IN TELOMERASE	SEQUENCE	LENGTH
5	36.	pep-RIA-35	[606-631]	VRQHQREARPALLTSRLRFIPKPDGLR	26 aa
	37.	pep-RIA-36	[607-631]	RQHQREARPALLTSRLRFIPKPDGLR	25 aa
	38.	pep-RIA-37	[608-631]	QHREARPALLTSRLRFIPKPDGLR	24 aa
10	39.	pep-RIA-38	[609-631]	HREARPALLTSRLRFIPKPDGLR	23 aa
	40.	pep-RIA-39	[610-631]	REARPALLTSRLRFIPKPDGLR	22 aa
	41.	pep-RIA-40	[605-627]	EVRQHQREARPALLTSRLRFIPKP	23 aa
	42.	pep-RIA-41	[605-628]	EVRQHQREARPALLTSRLRFIPKPD	24 aa
15	43.	pep-RIA-42	[605-629]	EVRQHQREARPALLTSRLRFIPKPDG	25 aa
	44.	pep-RIA-43	[605-630]	EVRQHQREARPALLTSRLRFIPKPDGL	26 aa
	45.	pep-RIA-44	[605-631]	EVRQHQREARPALLTSRLRFIPKPDGLR	27 aa
20	46.	pep-RIA-45	[605-632]	EVRQHQREARPALLTSRLRFIPKPDGLRP	28 aa
	47.	pep-RIA-46	[606-632]	VRQHQREARPALLTSRLRFIPKPDGLRP	27 aa
	48.	pep-RIA-47	[607-632]	RQHQREARPALLTSRLRFIPKPDGLRP	26 aa
	49.	pep-RIA-48	[608-632]	QHREARPALLTSRLRFIPKPDGLRP	25 aa
25	50.	pep-RIA-49	[609-632]	HREARPALLTSRLRFIPKPDGLRP	24 aa
	51.	pep-RIA-50	[610-632]	REARPALLTSRLRFIPKPDGLRP	23 aa
	52.	pep-RIA-51	[604-627]	AEVRQHQREARPALLTSRLRFIPKP	24 aa
30	53.	pep-RIA-52	[604-628]	AEVRQHQREARPALLTSRLRFIPKPD	25 aa
	54.	pep-RIA-53	[604-629]	AEVRQHQREARPALLTSRLRFIPKPDG	26 aa
	55.	pep-RIA-54	[604-630]	AEVRQHQREARPALLTSRLRFIPKPDGL	27 aa
35	56.	pep-RIA-55	[604-631]	AEVRQHQREARPALLTSRLRFIPKPDGLR	28 aa
	57.	pep-RIA-56	[604-632]	AEVRQHQREARPALLTSRLRFIPKPDGLRP	29 aa
	58.	pep-RIA-57	[604-633]	AEVRQHQREARPALLTSRLRFIPKPDGLRPI	30 aa
	59.	pep-RIA-58	[605-633]	EVRQHQREARPALLTSRLRFIPKPDGLRPI	29 aa
40	60.	pep-RIA-59	[606-633]	VRQHQREARPALLTSRLRFIPKPDGLRPI	28 aa
	61.	pep-RIA-60	[607-633]	RQHQREARPALLTSRLRFIPKPDGLRPI	27 aa
	62.	pep-RIA-61	[608-633]	QHREARPALLTSRLRFIPKPDGLRPI	26 aa
45	63.	pep-RIA-62	[609-633]	HREARPALLTSRLRFIPKPDGLRPI	25 aa
	64.	pep-RIA-63	[610-633]	REARPALLTSRLRFIPKPDGLRPI	24 aa
	65.	pep-RIA-64	[611-627]	EARPALLTSRLRFIPKP	17 aa
	66.	pep-RIA-65	[611-628]	EARPALLTSRLRFIPKPD	18 aa
50	67.	pep-RIA-66	[611-629]	EARPALLTSRLRFIPKPDG	19 aa
	68.	pep-RIA-68	[611-631]	EARPALLTSRLRFIPKPDGLR	21 aa
	69.	pep-RIA-69	[611-632]	EARPALLTSRLRFIPKPDGLRP	22 aa
55	70.	pep-RIA-70	[611-633]	EARPALLTSRLRFIPKPDGLRPI	23 aa
	71.	pep-RIA-71	[611-634]	EARPALLTSRLRFIPKPDGLRPIV	24 aa
	72.	pep-RIA-72	[611-635]	EARPALLTSRLRFIPKPDGLRPIVN	25 aa

EP 2 850 097 B1

(continued)

	SEQ ID NO	NAME	POSITION IN TELOMERASE	SEQUENCE	LENGTH
5	73.	pep-RIA-73	[611-636]	EARPALLTSRLRFIPKPDGLRPVNM	26 aa
	74.	pep-RIA-74	[611-637]	EARPALLTSRLRFIPKPDGLRPVNMMD	27 aa
	75.	pep-RIA-75	[611-638]	EARPALLTSRLRFIPKPDGLRPVNMMDY	28 aa
10	76.	pep-RIA-76	[611-639]	EARPALLTSRLRFIPKPDGLRPVNMMDYV	29 aa
	77.	pep-RIA-77	[611-640]	EARPALLTSRLRFIPKPDGLRPVNMMDYVV	30 aa
	78.	pep-RIA-78	[611-625]	EARPALLTSRLRFIP	15 aa
	79.	pep-RIA-79	[611-624]	EARPALLTSRLRFI	14 aa
15	80.	pep-RIA-80	[611-623]	EARPALLTSRLRF	13 aa
	81.	pep-RIA-81	[611-622]	EARPALLTSRLR	12 aa
	82.	pep-RIA-82	[611-621]	EARPALLTSRL	11 aa
20	83.	pep-RIA-83	[611-620]	EARPALLTSR	10 aa
	84.	pep-RIA-84	[611-619]	EARPALLTS	9 aa
	85.	pep-RIA-85	[611-618]	EARPALLT	8 aa
	86.	pep-RIA-86	[611-617]	EARPALL	7 aa
25	87.	pep-RIA-87	[611-616]	EARPAL	6 aa
	88.	pep-RIA-88	[611-615]	EARPA	5 aa
	89.	pep-RIA-89	[611-614]	EARP	4 aa
30	90.	pep-RIA-90	[611-613]	EAR	3 aa
	91.	pep-RIA-91	[612-626]	ARPALLTSRLRFIPK	15 aa
	92.	pep-RIA-92	[613-626]	RPALLTSRLRFIPK	14 aa
	93.	pep-RIA-93	[614-626]	PALLTSRLRFIPK	13 aa
35	94.	pep-RIA-94	[615-626]	ALLTSRLRFIPK	12 aa
	95.	pep-RIA-95	[616-626]	LLTSRLRFIPK	11 aa
	96.	pep-RIA-96	[617-626]	LTSRLRFIPK	10 aa
40	97.	pep-RIA-97	[618-626]	TSRLRFIPK	9 aa
	98.	pep-RIA-98	[619-626]	SRLRFIPK	8 aa
	99.	pep-RIA-99	[620-626]	RLRFIPK	7 aa
45	100.	pep-RIA-100	[621-626]	LRFIPK	6 aa
	101.	pep-RIA-101	[622-626]	RFIPK	5 aa
50	102.	pep-RIA-102	[623-626]	FIPK	4 aa
	103.	pep-RIA-103	[624-626]	IPK	3 aa
55	104.	pep-RIA-104	[612-625]	ARPALLTSRLRFIP	14 aa
	105.	pep-RIA-105	[613-624]	RPALLTSRLRFI	12 aa

EP 2 850 097 B1

(continued)

	SEQ ID NO	NAME	POSITION IN TELOMERASE	SEQUENCE	LENGTH
5	106.	pep-RIA-106	[614-623]	PALLTSRLRF	10 aa
	107.	pep-RIA-107	[615-622]	ALLTSRLR	8 aa
10	108.	pep-RIA-108	[616-621]	LLTSRL	6 aa
	109.	pep-RIA-109	[617-620]	LTSR	4 aa
15	110.	pep-RIA-110	[612-624]	ARPALLTSRLRFI	13 aa
	111.	pep-RIA-111	[612-623]	ARPALLTSRLRF	12 aa
20	112.	pep-RIA-112	[612-622]	ARPALLTSRLR	11 aa
	113.	pep-RIA-113	[612-621]	ARPALLTSRL	10 aa
25	114.	pep-RIA-114	[612-620]	ARPALLTSR	9 aa
	115.	pep-RIA-115	[612-619]	ARPALLTS	8 aa
30	116.	pep-RIA-116	[612-618]	ARPALLT	7 aa
	117.	pep-RIA-117	[612-617]	ARPALL	6 aa
35	118.	pep-RIA-118	[612-616]	ARPAL	5 aa
	119.	pep-RIA-119	[612-615]	ARPA	4 aa
40	120.	pep-RIA-120	[612-614]	ARP	3 aa
	121.	pep-RIA-121	[613-625]	RPALLTSRLRFIP	13 aa
45	122.	pep-RIA-122	[613-623]	RPALLTSRLRF	11 aa
	123.	pep-RIA-123	[613-622]	RPALLTSRLR	10 aa
50	124.	pep-RIA-124	[613-620]	RPALLTSR	8 aa
	125.	pep-RIA-125	[613-619]	RPALLTS	7 aa
55	126.	pep-RIA-126	[613-618]	RPALLT	6 aa
	127.	pep-RIA-127	[613-617]	RPALL	5 aa

EP 2 850 097 B1

(continued)

	SEQ ID NO	NAME	POSITION IN TELOMERASE	SEQUENCE	LENGTH
5	128.	pep-RIA-128	[613-616]	RPAL	4 aa
	129.	pep-RIA-129	[613-615]	RPA	3 aa
10	130.	pep-RIA-130	[614-625]	PALLTSRLRFIP	12 aa
	131.	pep-RIA-131	[614-624]	PALLTSRLRFI	11 aa
15	132.	pep-RIA-132	[614-622]	PALLTSRLR	9 aa
	133.	pep-RIA-133	[614-621]	PALLTSRL	8 aa
20	134.	pep-RIA-134	[614-620]	PALLTSR	7 aa
	135.	pep-RIA-135	[614-619]	PALLTS	6 aa
25	136.	pep-RIA-136	[614-618]	PALLT	5 aa
	137.	pep-RIA-137	[614-617]	PALL	4 aa
30	138.	pep-RIA-138	[614-616]	PAL	3 aa
	139.	pep-RIA-139	[615-625]	ALLTSRLRFIP	11 aa
35	140.	pep-RIA-140	[615-623]	ALLTSRLRF	9 aa
	141.	pep-RIA-141	[615-621]	ALLTSRL	7 aa
40	142.	pep-RIA-142	[615-620]	ALLTSR	6 aa
	143.	pep-RIA-143	[615-619]	ALLTS	5 aa
45	144.	pep-RIA-144	[615-618]	ALLT	4 aa
	145.	pep-RIA-145	[615-617]	ALL	3 aa
50	146.	pep-RIA-146	[616-625]	LLTSRLRFIP	10 aa
	147.	pep-RIA-147	[616-624]	LLTSRLRFI	9 aa
55	148.	pep-RIA-148	[616-623]	LLTSRLRF	8 aa
	149.	pep-RIA-149	[616-622]	LLTSRLR	7 aa

EP 2 850 097 B1

(continued)

	SEQ ID NO	NAME	POSITION IN TELOMERASE	SEQUENCE	LENGTH
5	150.	pep-RIA-150	[616-620]	LLTSR	5 aa
	151.	pep-RIA-151	[616-619]	LLTS	4 aa
10	152.	pep-RIA-152	[616-618]	LLT	3 aa
	153.	pep-RIA-153	[617-625]	LTSRLRFIP	9 aa
15	154.	pep-RIA-154	[617-624]	LTSRLRFI	8 aa
	155.	pep-RIA-155	[617-623]	LTSRLRF	7 aa
20	156.	pep-RIA-156	[617-622]	LTSRLR	6 aa
	157.	pep-RIA-157	[617-621]	LTSRL	5 aa
25	158.	pep-RIA-158	[617-619]	LTS	3 aa
	159.	pep-RIA-159	[618-625]	TSRLRFIP	8 aa
30	160.	pep-RIA-160	[618-624]	TSRLRFI	7 aa
	161.	pep-RIA-161	[618-623]	TSRLRF	6 aa
35	162.	pep-RIA-162	[618-622]	TSRLR	5 aa
	163.	pep-RIA-163	[618-621]	TSRL	4 aa
40	164.	pep-RIA-164	[618-620]	TSR	3 aa
	165.	pep-RIA-165	[619-625]	SRLRFIP	7 aa
45	166.	pep-RIA-166	[619-624]	SRLRFI	6 aa
	167.	pep-RIA-167	[619-623]	SRLRF	5 aa
50	168.	pep-RIA-168	[619-622]	SRLR	4 aa
	169.	pep-RIA-169	[619-621]	SRL	3 aa
55	170.	pep-RIA-170	[620-625]	RLRFIP	6 aa
	171.	pep-RIA-171	[620-624]	RLRFI	5 aa

EP 2 850 097 B1

(continued)

SEQ ID NO	NAME	POSITION IN TELOMERASE	SEQUENCE	LENGTH
172.	pep-RIA-172	[620-623]	RLRF	4 aa
173.	pep-RIA-173	[620-622]	RLR	3 aa
174.	pep-RIA-174	[621-625]	LRFIP	5 aa
175.	pep-RIA-175	[621-624]	LRFI	4 aa
176.	pep-RIA-176	[621-623]	LRF	3 aa
177.	pep-RIA-177	[622-625]	RFIP	4 aa
178.	pep-RIA-178	[622-624]	RFI	3 aa
179.	pep-RIA-179	[623-625]	FIP	3 aa
180.	Telomerase	[1-1132]	MPRAPRCRAVRSLLRSHYREVLPATFVRR LGPQGWRLVQRGDPAAFRALVAQCLVCVP WDARPPPAAPSFRQVSCLKELVARVLQRL CERGAKNVLAFGFALLDGARGGPPEAFTTS VRSYLPNTVTDALRGSGAWGLLLRRVGDD VLVHLLARCALFVLVAPSCAYQVCGPPLYQ LGAATQARPPPHASGPRRRLGCERAWNHS VREAGVPLGLPAPGARRRGGSASRSLPLPK RPRRGAAPEPERTPVGQGSWAHPGRTRG PSDRGFCVVSAPPAEEATSLEGALSGTR HSHPSVGRQHHAGPPSTSRPPRPWDTPCP PVYAETKHFYSSGDKEQLRPSFLLSSLRP SLTGARRLVETIFLGSRPWMPGTPRRLPRL PQRYWQMRPLFLELLGNHAQCPYGVLLKT HCPLRAAVTPAAGVCAREKPQGSVAAPEE EDTDPRLVQLLRQHSSPWQVYGFVRACL RRLVPPGLWGSRHNERFLRNTKKFISLG KHAKLSLQELTW KMSVRDCAWLRRSPGVGCVPAAEHRLRE EILAKFLHWLMSVYVVELLSFFYVTETTFQ KNRLFFYRKSWSKLQSIGIRQHLKRVQL RELSEAEVRQHREARPALLTSRLRFIPKPD GLRPIVNMDYVVGARTFRREKRAERLTSRV	1132 aa

(continued)

SEQ ID NO	NAME	POSITION IN TELOMERASE	SEQUENCE	LENGTH
5			KALFSVLNYERARRPGLLGASVLGLDDIHR	
			AWRTFVLRVRAQDPPELYFVKVDVTGAY	
10			DTIPQDRLTEVIASIIKPQNTYCVRRYAVVQ	
			KAAHGHVRKAFKSHVSTLTDLQPYMRQFV	
			AHLQETSPLRDAVVIEQSSSLNEASSGLFD	
15			VFLRFMCHHAVRIRGKSYVQCQGIPQGSIL	
			STLLCSLCYGD MENKLFAGIRRDGLLLRLV	
			DDFLLVTPHLTHAKTFLRTLVRGVPEYGCV	
			VNLRKTVVNFVVEDEALGGTAFVQMPAHG	
20			LFPWCGLLLDTRTLEVQSDYSSYARTSIRA	
			SLTFNRGFKAGRNMRRKLFGLVRLKCHSL	
			FLDLQ	
			VNSLQTVCTNIYKILLQAYRFHACVLQLPF	
25			HQQVWKNPTFFLRVISDTASLCYSILKAKN	
			AGMSLGAKGAAGPLPSEAVQWLCHQAFLL	
			KLTRHRVTYVPLLGLSLRTAQTQLSRKLPGT	
30			TLTALEAAANPALPSDFKTILD	

[0038] In one embodiment of the present invention, a polynucleotide that codes a peptide with anti-inflammatory activities is provided. The polynucleotide codes a peptide selected from the group consisting of SEQ ID NO: 116, 117, and 118. The polynucleotide mentioned above enables production of the peptides in large quantities. For example, cultivation of vectors that include polynucleotides encoding peptides allows production of peptides in large quantities.

[0039] In the present specification and claims, the terms "homology" and "sequence identity" are used interchangeably to indicate the degree of sequence overlap between two amino acid (or if relevant: nucleic acid) sequences.

[0040] Unless otherwise stated the term "Sequence identity" for peptides as used herein refers to the sequence identity calculated as $(n_{ref} - n_{dif}) \cdot 100 / n_{ref}$, wherein n_{dif} is the total number of non-identical residues in the two sequences when aligned so that a maximum number of amino acids are identical and wherein n_{ref} is the number of residues in the shortest of the sequences. Hence, the DNA sequence atgcagtc will have a sequence identity of 75% with the sequence aatcaatc ($n_{dif}=2$ and $n_{ref}=8$).

[0041] In some embodiments the sequence identity is determined by conventional methods, e.g., Smith and Waterman, 1981, Adv. Appl. Math. 2:482, by the search for similarity method of Pearson & Lipman, 1988, Proc. Natl. Acad. Sci. USA 85:2444, using the CLUSTAL W algorithm of Thompson et al., 1994, Nucleic Acids Res 22:467380, by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group). The BLAST algorithm (Altschul et al., 1990, Mol. Biol. 215:403-10) for which software may be obtained through the National Center for Biotechnology Information www.ncbi.nlm.nih.gov/ may also be used. When using any of the aforementioned algorithms, the default parameters for "Window" length, gap penalty, etc., are used.

[0042] Changes in amino acid sequence belong to the modification of peptide's physical and chemical characteristics. For example, amino acid transformation can be performed by improving thermal stability of the peptide, altering substrate specificity, and changing the optimal pH.

[0043] In one embodiment of the present invention, a peptide consisting of SEQ ID NO: 116, 117, or 118 originates from telomerase, more specifically, telomerase of *Homo sapiens*.

[0044] The term "amino acid" herein includes not only the 22 standard amino acids that are naturally integrated into peptide but also the D-isomers and transformed amino acids. Therefore, in a specific embodiment of the present invention, a peptide herein includes a peptide having D-amino acids. On the other hand, a peptide may include non-standard amino acids such as those that have been post-translationally modified. Examples of post-translational modification include

phosphorylation, glycosylation, acylation(including acetylation, myristoylation, plamitoylation), alkylation, carboxylation, hydroxylation, glycation, biotinylation, ubiquitinylation, transformation in chemical properties (e.g. β -removing deimida-
tion, deamidation) and structural transformation (e.g. formation of disulfide bridge). Also, changes of amino acids are
included and the changes of amino acids occur due to chemical reaction during the combination process with crosslinkers
for formation of a peptide conjugate.

[0045] A peptide disclosed herein may be a wild-type peptide that has been identified and isolated from natural sources. On the other hand, when compared to peptide fragments of SEQ ID NO: 1, the peptides disclosed herein may be artificial mutants that comprise one or more substituted, deleted and/or inserted amino acids. Amino acid alteration in wild-type polypeptide - not only in artificial mutants - comprises conservative substitution of amino acids that do not influence protein folding and or activation. Examples of conservative substitution belong to the group consisting of basic amino acids (arginine, lysine and histidine), acidic amino acids (glutamic acid and aspartic acid), polar amino acids (glutamine and asparagines), hydrophobic amino acids (leucine, isoleucine, valine and methionine), aromatic amino acids (phenylalanine, tryptophan and tyrosine), and small amino acids (glycine, alanine, serine, and threonine). The amino acid substitutions that do not generally alter the specific activity are known in the art of the present invention. Most common occurred alteration are Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Tyr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, Asp/Gly, and the opposite alterations. Another example of conservative substitutions are shown in the following table 2.

Table 2.

Original amino acid	Examples of residue substitution	Preferable residue substitution
Ala (A)	val; leu; ile	Val
Arg (R)	lys; gln; asn	Lys
Asn (N)	gin; his; asp, lys; arg	Gln
Asp (D)	glu; asn	Glu
Cys (C)	ser; ala	Ser
Gln (Q)	asn; glu	Asn
Glu (E)	asp; gln	Asp
Gly (G)	ala	Ala
His (H)	asn; gln; lys; arg	Arg
Ile (I)	leu; val; met; ala; phe; norleucine	Leu
Leu (L)	norleucine; ile ; val; met; ala; phe	Ile
Lys (K)	arg; gln; asn	Arg
Met (M)	leu; phe; ile	Leu
Phe (F)	leu; val; ile; ala; tyr	Tyr
Pro (P)	ala	Ala
Ser (S)	thr	Thr
Thr(T)	ser	Ser
Trp (W)	tyr; phe	Tyr
Tyr (Y)	trp; phe ; thr; ser	Phe
Val (V)	ile; leu; met; phe; ala; norleucine	Leu

[0046] The substantial transformation of the biological properties of peptides are performed by selecting significantly different substitution in the following efficacies: (a) the efficacy in maintaining the structure of the polypeptide backbone in the area of substitution, such as sheet or helical three-dimensional structures, (b) the efficacy in maintaining electrical charge or hydrophobicity of the molecule in the target area, or (c) the efficacy of maintaining the bulk of the side chain. Natural residues are divided into groups by general side chain properties as the following:

(1) hydrophobicity: Norleucine, met, ala, val, leu, ile;

(2) neutral hydrophilicity: cys, ser, thr;

(3) acidity: asp, glu;

(4) basicity: asn, gin, his, lys arg;

(5) residue that affects chain orientation: gly, pro; and

(6) aromaticity: trp, tyr, phe.

[0047] Non-conservative substitutions may be performed by exchanging a member of the above classes to that of a different class. Any cysteine residues that are not related in maintaining the proper three-dimensional structure of the peptide can typically be substituted into serine, thus increasing the oxidative stability of the molecule and preventing improper crosslinkage. Conversely, improvement of stability can be achieved by adding cysteine bond(s) to the peptide.

[0048] Altered types of amino acids variants of peptides are those that antibody glycosylation pattern changed. The term "change" herein relates to deletion of carbohydrate residues and/or addition of at least one glycosylated residues that do not exist within a peptide.

[0049] Glycosylation in peptides are typically N-connected or O-connected. The term "N-connected" herein relates to that carbohydrate residues are attached to the side chain of asparagine residues. As tripeptide sequences, asparagine-X-serine and asparagine-X-threonine (where the X is any amino acid except proline) are the recognition sequence for attaching carbohydrate residue enzymatically to the side chain of asparagine. Therefore, with the presence of one of these tripeptide sequences in a polypeptide, the potential glycosylation sites are created. "O-connected glycosylation" means attaching one of sugar N-acetylgalactosamine, galactose, or xylose to hydroxyl amino acids. The hydroxyl amino acids are most typically serine or threonine, but 5-hydroxyproline or 5-hydroxylysine can be used.

[0050] Addition of glycosylation site to a peptide is conveniently performed by changing amino acid sequence to contain tripeptide sequence mentioned above (for N-linked glycosylation sites). These changes may be made by addition of at least one serine or threonine residues to the first antibody sequence, or by substitution with those residues (for O-linked glycosylation sites).

[0051] In one embodiment of the present invention, a polynucleotide is a nucleic acid molecule that can be spontaneous or artificial DNA or RNA molecules, either single-stranded or doublestranded. The nucleic acid molecule can be one or more nucleic acids of same type (for example, having a same nucleotide sequence) or nucleic acids of different types. The nucleic acid molecules comprise one or more DNA, cDNA, decoy DNA, RNA, siRNA, miRNA shRNA, stRNA, snoRNA, snRNA PNA, antisense oligomer, plasmid and other modified nucleic acids, but not limited to those.

[0052] A HMGB1 protein is known as a cytokine. It first undergoes acetylation and translocation to cytoplasm by external stimulation. Then it is secreted out of the cell, therefore serving the role of inflammation-causing cytokine. Because when one has an inflammation due to such activity, HMGB1 protein is secreted out of the cell, and patients with inflammatory diseases such as Churg strauss syndrome, rheumatoid arthritis and Sjogren's syndrome will present with elevated serum levels of HMGB1. Hence, if nucleus contains large amount of HMGB1 even when there is a stimulus that causes inflammation, it is suggestive of the fact that HMGB1 is not being secreted out of the cell, which means inflammation is being suppressed.

[0053] In one embodiment of the present invention, when a cell is treated with a peptide of the invention, the amount of HMGB1 within the nucleus increases. This represents that the peptides mentioned above have excellent inflammation preventive or suppressive effects.

[0054] Also, in specific embodiments of the present invention, a peptide of the invention has an advantage in that it has high feasibility due to its low toxicity within a cell.

[0055] In the present invention, an "inflammatory disease" is a broad indication that refers to any disease that designates inflammation as a main cause or inflammation caused by disease. Specifically, an inflammatory disease includes (1) general or localized inflammatory disease (for example, allergies; immune-complex disease; hayfever; hypersensitive shock; endotoxin shock; cachexia, hyperthermia; granulomatosis; or sarcoidosis); (2) gastro-intestinal related diseases (for example, appendicitis; gastric ulcer; duodenal ulcer; peritonitis; pancreatitis; ulcerative, acute, or ischemic colitis; cholangitis; cholecystitis, steatorrhea, hepatitis, Crone's disease; or Whipple's Disease); (3) dermal related diseases (for example, psoriasis; burns; sunburns; dermatitis; Urticarial warts or wheal); (4) vascular related diseases (for example, angiitis; vasculitis; endocarditis; arteritis; atherosclerosis; thrombophlebitis; pericarditis; congestive heart failure; myocarditis; myocardial ischemia; periarteritis nodosa; recurrent stenosis; Buerger's disease; or rheumatic fever); (5) respiratory diseases (for example, asthma; epiglottitis; bronchitis; emphysema; rhinitis; cystic fibrosis; interstitial pneumonitis; COPD(chronic obstructive pulmonary disease); adult respiratory distress syndrome; coniosis; alveolitis; bronchiolitis; pharyngitis; pleurisy; or sinusitis); (6) bone, joint, muscle and connective tissue related diseases (for example, eosinophilic granuloma; arthritis; arthralgia; osteomyelitis; dermatomyositis; fasciitis; Paget's disease; gout; periodontal disease;

rheumatoid arthritis; myasthenia gravis; ankylosing spondylitis; or synovitis); (7) urogenital disorders (for example, epididymitis; vaginitis; prostatitis; or urethritis); (8) central or peripheral nervous system related diseases (for example, Alzheimer's disease; meningitis; encephalitis; multiple sclerosis; cerebral infarction; cerebral embolism; Guillain-Barre syndrome; neuritis; neuralgia; spinal cord injury; paralysis; or uveitis); (9) virus (for example, influenza; respiratory syncytial virus; HIV; hepatitis B; hepatitis C; or herpes virus), infectious disease (for example, Dengue fever; or septicemia), fungal infection (for example, candidiasis); or bacterial, parasitic, and similar microbial infection (for example, disseminated bacteremia; malaria; onchocerciasis; or amebiasis); (10) autoimmune disease (for example, thyroiditis; lupus; Goodpasture's syndrome; allograft rejection; graft versus host disease; or diabetes); and (11) cancer or tumor disease (for example, Hodgkin's disease), but not limited to those.

[0056] Treating the inflammatory component of such diseases has been a major goal of the global pharmaceutical industry for a number of decades, and a wide variety of useful treatments have been developed. Examples include the corticosteroids (a range of natural, semisynthetic and synthetic agents designed to mimic the effect of cortisol, including prednisolone, methylprednisolone, dexamethasone, betamethasone, fluticasone and so forth), cyclooxygenase inhibitors (both non-selective or cox-1 selective, such as indomethacin, sulfasalazine and aspirin, and more recently cox-2 selective, such as celecoxib), leukotriene blockers (such as montelukast) and anti-TNFs (such as modified monoclonal neutralising antibodies, including infliximab (Remicade™) and adalimumab (Humira™), TNF receptor fusion proteins, such as etanercept (Enbrel™), as well as small molecule TNF- α synthesis inhibitors like thalidomide).

[0057] In one embodiment of the present invention, an anti-inflammatory composition comprising a peptide of the invention as an active ingredient is provided.

[0058] In one embodiment of the present invention, the anti-inflammatory composition may contain 0.1 $\mu\text{g}/\text{mg}$ to 1 mg/mg , specifically 1 $\mu\text{g}/\text{mg}$ to 0.5 mg/mg , more specifically 10 $\mu\text{g}/\text{mg}$ to 0.1 mg/mg of a peptide of the invention.

[0059] When the peptide is contained in the above mentioned range, all the safety and stability of the composition may be satisfied and appropriate in terms of cost-effectiveness.

[0060] In one embodiment of the present invention, the composition may have application with all animals including human, dog, chicken, pig, cow, sheep, guinea pig, and monkey.

[0061] In one embodiment of the present invention, the medical composition for the use of treatment or prophylaxis of inflammatory disease with an active ingredient that is comprised of a peptide of the invention is provided. In one embodiment of the present invention, the pharmaceutical composition may be administered through oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, in the bone marrow, epidural or subcutaneous means.

[0062] Forms of oral administration may be, but not limited to, tablets, pills, soft or hard capsules, granules, powders, solution, or emulsion. Forms of non-oral administration may be, but not limited to, injections, drips, lotions, ointments, gels, creams, suspensions, emulsions, suppository, patch, or spray.

[0063] In one embodiment of the present invention, the pharmaceutical composition, if necessary, may contain additives, such as diluents, excipients, lubricants, binders, disintegrants, buffers, dispersants, surfactants, coloring agents, aromatics or sweeteners. In one embodiment of the present invention, the pharmaceutical composition can be manufactured by conventional methods of the industry in the art.

[0064] In one embodiment of the present invention, the active ingredient of the medical composition may vary according to the patient's age, sex, weight, pathology and state, administration route, or prescriber's judgment. Dosage based on these factors is determined within levels of those skilled in the art, and the daily dose for example may be, but not limited to, 0.1 $\mu\text{g}/\text{kg}/\text{day}$ to 1 $\text{g}/\text{kg}/\text{day}$, specifically 1 $\mu\text{g}/\text{kg}/\text{day}$ to 10 $\text{mg}/\text{kg}/\text{day}$, more specifically the 10 $\mu\text{g}/\text{kg}/\text{day}$ to 1 $\text{mg}/\text{kg}/\text{day}$, more specifically the 50 $\mu\text{g}/\text{kg}/\text{day}$ to 100 $\mu\text{g}/\text{kg}/\text{day}$. In one embodiment of the present invention, the pharmaceutical composition may be administered, but not limited to, 1 to 3 times a day.

[0065] In one embodiment of the present invention, a skin external composition for improvement or prevention of skin inflammation is provided. The skin external composition contains an active ingredient that is a peptide of the invention.

[0066] In another embodiment of the present invention, a cosmetic composition for improvement or prevention of skin inflammation is provided. The cosmetic composition contains an active ingredient that is a peptide of the invention.

[0067] In one embodiment of the present invention, external application composition or cosmetic composition may be provided in all forms appropriate for topical applications. For example, forms can be provided as solutions, emulsions obtained by dispersion of oil phase in water, emulsion obtained by dispersion of water in oil phase, suspension, solid, gel, powder, paste, foam or aerosol. These forms can be manufactured by conventional methods of the industry in the art.

[0068] In one embodiment of the present invention, the cosmetic composition may include, within levels that will not harm the main effect, other ingredients that can desirably increase the main effect. In one embodiment of the present invention, the cosmetic composition may additionally include moisturizer, emollient agents, surfactants, UV absorbers, preservatives, fungicides, antioxidants, pH adjusting agent, organic or inorganic pigments, aromatics, cooling agent or antiperspirant. The formulation ratio of the above-mentioned ingredients can be decided by those skilled in the art within levels that will not harm the purpose and the effects of the present invention, and the formulation ratio based on total weight of the cosmetic composition can be 0.01 to 5% by weight, specifically 0.01 to 3% by weight.

[0069] In one embodiment of the present invention, a food composition for inflammation prevention or suppression is

provided. The food composition contains an active ingredient that is a peptide of the invention.

[0070] In one embodiment of the present invention, food composition is not limited to forms, but for example may be granules, powder, liquid, and solid forms. Each form can be formed with ingredients commonly used in the industry appropriately chosen by those skilled in the art, in addition to the active ingredient, and can increase the effect with other ingredients.

[0071] Decision for dosage on the above-mentioned active ingredient is within the level of those skilled in the art, and daily dosage for example may be 1 μg / kg / day to 10 mg / kg / day, more specifically the 10 μg / kg / day to 1 mg / kg / day, more specifically the 50 μg / kg / day to 100 μg / kg / day, but not limited to these numbers and can vary according to age, health status, complications and other various factors.

[0072] In one embodiment of the present invention, a peptide of the invention is for use in prevention or treatment of inflammatory disease.

[0073] In one embodiment of the present invention, a kit for prophylaxis or treatment of inflammatory diseases is provided. The kit contains :a peptide with anti-inflammatory activity or a composition comprising the peptide, of the invention; and instructions including at least one of administration dose, administration route, administration frequency, and indication of the peptide or composition.

[0074] The terms used herein is intended to be used to describe the embodiments, not to limit the present invention. Terms without numbers in front are not to limit the quantity but to show that there may be more than one thing of the term used. The term "including", "having", "consisting", and "comprising" shall be interpreted openly (i.e. "including but not limited to").

[0075] Mention of range of numbers is used instead of stating separate numbers within the range, so unless it is explicitly stated, each number can be read as separate numbers integrated herein. The end values of all ranges are included in the range and can be combined independently.

[0076] Unless otherwise noted or clearly contradicting in context, all methods mentioned herein can be performed in the proper order. The use of any one embodiment and all embodiment, or exemplary language (e.g., that use "like ~"), unless included in the claims, is used to more clearly describe the present invention, not to limit the scope of the present invention. Any language herein outside of the claims should not be interpreted as a necessity of the present invention. Unless defined otherwise, technical and scientific terms used herein have meaning normally understood by a person skilled in the art that the present invention belongs to.

[0077] The preferred embodiments of the present invention are the best mode known to the inventors to perform the present invention. It may become clear to those skilled in the art after reading the statements ahead of the variations in the preferred embodiments. The present inventors hope that those skilled in the art can use the variations adequately and present invention be conducted in other ways than listed herein. Thus, the present invention, as allowed by the patent law, includes equivalents, and variations thereof, of the key points of the invention stated in the appended claims. In addition, all possible variations within any combination of the above-mentioned components are included in the present invention, unless explicitly stated otherwise or contradicting in context. Although the present invention is described and shown by exemplary embodiments, those skilled in the art will understand well that there can be various changes in the form and details without departing from the spirit of the invention and range, defined by the claims below.

[0078] Tumor necrosis factor (TNF), particularly TNF- α , is known to be released from inflammatory cells and cause various cytotoxic reactions, immunological reactions and inflammatory reactions. TNF- α is known to be involved in the occurrence and prolongation of many inflammatory and autoimmune diseases and further cause serious septicemia and septic shock when it is released into the blood and acts systemically. Because TNF- α is a factor associated widely with the immune system of a living body, the development of agents inhibiting TNF- α is actively carried out. TNF- α is biosynthesized in an inactive form and becomes an active form by being cleaved by protease; the enzyme responsible for the activation is called a tumor necrosis factor-converting enzyme (TACE). Thus, a substance inhibiting this TACE can treat, improve, or prevent diseases, pathologic conditions, abnormal conditions, troubles, adverse symptoms and the like ascribed to TNF- α (KR2011-0060940A).

[0079] High-mobility group box 1(HMGB1) protein exists in high concentrations in thymus, lymph nodes, testes, and in fetal liver, and with exception to liver and brain cells, usually exists inside of the nucleus. The said HMGB1 protein has 3 domains consisting of A-box, B-box, and C-terminal.

[0080] It was reported by Tracey et al., 1999 that HMGB1 protein has a role as a cytokine which induces inflammation, and the mechanism of said HMGB1's inflammation induction is by an external stimulus causing acetylation of HMGB1 which then moves from the nucleus into the cytoplasm. Afterward, it is known to be secreted out of the cell, or secreted out from the cell in necrosis. (Bonaldi T et al., EMBO J, (22)5551-60, 2003).

[0081] The invention is further described by the figures, the following examples and experiments, which are solely for the purpose of illustrating specific embodiments of this invention, and are not to be construed as limiting the scope of the invention in any way.


EXAMPLE 1

Synthesis of PEP-1 and Measurement of anti-inflammatory activities of PEP-1 (SEQ ID NO: 1)

5 Experiment 1. Synthesis of PEP-1 (SEQ ID NO: 1)

[0082] A peptide comprised of 16 amino acids with the chemical structure 1 as below having the sequence SEQ ID: 1 (PEP-1) derived from human telomerase was synthesized:

10 <Chemical Structure 1>



[0083] SEQ ID NO: 1 (PEP-1) was synthesized according to the existing method of solid phase peptide synthesis. In detail, the peptides were synthesized by coupling each amino acid from C-terminus through Fmoc solid phase peptide synthesis, SPPS, using ASP48S (Pepton, Inc., Daejeon ROK). Those peptides with their first amino acid at the C-terminus being attached to resin were used as follows:

NH₂-Lys(Boc)-2-chloro-Trityl Resin

50 NH₂-Ala-2-chloro-Trityl Resin

NH₂-Arg(Pbf)-2-chloro-Trityl Resin

[0084] All the amino acid materials to synthesize the peptide were protected by Fmoc at the N-terminus, and the amino acid residues were protected by Trt, Boc, t-Bu (t-butylester), Pbf (2,2,4,6,7-pentamethyl dihydro-benzofuran-5-sulfonyl) that can be dissolved in acid. Such as:

Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Pro-OH, Fmoc-Leu-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Met-OH,

Fmoc-Asn(Trt)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Ahx-OH, Trt-Mercaptoacetic acid.

[0085] HBTU[2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylammonium hexafluorophosphate] / HOBt [N-Hydroxybenzotriazole] / NMM [4-Methylmorpholine] were used as the coupling reagents. In 20% of DMF, piperidine was used to remove Fmoc. In order to remove the protection from residue or to separate the synthesized peptide from Resin, cleavage cocktail [TFA (trifluoroacetic acid) / TIS (triisopropylsilane) / EDT (ethanedithiol) / H₂O=92.5/2.5/2.5/2.5] was used.

[0086] Synthesized the peptide by using the solid phase scaffold combined to starting amino acid with the amino acid protection, reacting the corresponding amino acids separately, washing with solvent and deprotected, and repeating the process. After cutting off the synthesized peptide from the resin, it was purified by HPLC and verify for synthesis by MS, and then freeze-dried.

[0087] Specific synthesis process of PEP 1 is described by the following.

1) Coupling

Melted the amino acid (8 equivalent) protected with NH₂-Lys(Boc)-2-chloro-Trityl Resin, and coupling agent HBTU(8 equiv.)/HOBt(8equiv.)/NMM(16 equiv.) and added to DMF, then let react in room temperature for 2 hours, then washed with DMF, MeOH, and DMF in that order.

2) Fmoc deprotection

Added 20% piperidine in DMF and reacted in room temperature for 5 minutes 2 times, then washed with DMF, MeOH, and DMF in that order.

3) Make the basic framework of peptide by repeating reactions 1 and 2 repeatedly.

4) Cleavage: Add Cleavage Cocktail to the completely synthesized peptide and separated the peptide from the resin.

5) Add cooling diethyl ether into obtained mixture, and then centrifugation is used to precipitate gathered peptide.

6) After purification by Prep-HPLC, check the molecular weight by LC/MS and lyophilize to produce in powder form.

Experiment 2: Anti-inflammatory activity measurement of PEP 1

Cell lines culture

[0088] Raw 264.7 macrophage cell (KCBL, 40071) from Korea Cell Bank was maintained in Dulbecco's modified Eagle's medium (DMEM; PAA, Austria) containing 10% fetal bovine serum (FBS; Gibco Laboratories), 100 unit/mL of streptomycin, and penicillin (Gibco Laboratories) at 37°C with 5% CO₂. Raw264.7 cells were seeded into a 96-well plate at a density of 1 × 10⁶ cells/mL and incubated overnight.

[0089] On the following day, the medium was replaced with fresh medium and 5 μg/mL of peptide (obtained as described in Experiment example 1) was added to the cells. After 30 min incubation of cells with the peptide 50 μl of LPS (to a final concentration of 1 μg/mL) was added, and cells were incubated for additional 24 hr. The experimental sample with the induction of inflammatory response was treated with 1 μg/mL mL lipopolysaccharide (LPS; Sigma, USA) and control sample was treated with phosphate buffered saline (PBS; pH 7.2). The supernatant samples from each condition was collected in eppendorf tubes and subjected to further analysis.

Experiment 2-1. NO level analysis

[0090] The level of nitric oxide (NO) was measured in Raw 264.7 cell (1 × 10⁶ cell/ml) using Griess reagent system (Promega, USA). Culture medium of 50 μl was added to a 96-well plate and Griess reagent I (NED) solution and Griess reagent II (Sulfanilamide solution) are added in the same amount. After 10 min incubation of cells with the reagents, the optical density at 540nm was measured within 30 min using a microplate reader (Molecular Devices, USA). The concentration of NO was calculated by using a standard curve (0~100 μM) of sodium nitrite.

[0091] As shown in Table 3 below, stimulation of cells with LPS increased the expression of NO, but in co-treatment with LPS and Pep1, the expression level of NO mentioned above decreased. NO is produced during inflammation, and the result showing Pep1 reduced NO level to 65% of the control strongly support the anti-inflammatory effect of Pep1.

Table 3. The measurement of anti-inflammatory effect of human telomerase derived PEP 1

Test sample	NO Expression Level of control (%)	Decreased NO Expression Level (%)
PBS	0	-

(continued)

Test sample		NO Expression Level of control (%)	Decreased NO Expression Level (%)
LPS 1 µg/mL	PBS	100	0
	PEP 1 (0.5 µg/mL)	35	65

Experiment 2-2. Analysis of cytokine inhibitory effect

[0092] To investigate the effect of PEP1 on inhibiting proinflammatory cytokine production RAW 264.7 cell were pre-treated with PEP 1 at a concentration of 5 µg/mL challenged with LPS at a concentration of 1 µg/mL, and cells were further incubated for 24 hr. The supernatant samples containing cell culture medium was collected and analyzed for the cytokine levels using ELISA kits (eBioscience, San Diego).

[0093] 96 wells plates were coated with 100 µL of capture antibodies (diluted in coating buffer to the concentration recommended by manufacturer's protocol) overnight at 4°C. Then, after washing the plates 5 times, 200 µl of assay diluents was added to each well and incubated for 1 hr at room temperature for blocking. After washing each well with wash buffer five times, cell culture sample or each cytokine standard protein sample was diluted and 100 µl of each added into each well. The plate containing samples were incubated overnight at 4 °C. Then, after washing the plate five times with the wash buffer, 100 µl of secondary antibody conjugated to avidin was added and incubated for 1 hr at room temperature.

[0094] Following incubation with the secondary antibody, the plate was washed five times and incubated with 100µl of avidin-HRP (BD Bioscience) for 30 min at room temperature. After washing the plate seven times, 100 µl of TMB solution (Pierce) was added and incubated for 15 min at room temperature. The reaction was stopped by adding 50 µl of 2N H₂SO₄ in each well. The optical density at 450nm was measured using a microplate reader. Statistical analysis was performed by variance analysis using ANOVA procedure of SPSS program, and verified the significance between analyses using Duncan's multiple range test.

Experiment 2-3. IL-6 secretion measurement

[0095] As shown in Table 4 below, treatment with LPS alone increased the cytokine IL-6 (interleukin-6) secretion. However, co- treatment with LPS and PEP-1 showed a decrease in the level of the proinflammatory cytokine IL-6 secretion. More importantly, after the treatment with PEP-1, the level of proinflammatory cytokine secretion decreased by more than 70%, which indicates a robust anti-inflammatory effect of Pep1.

Table 4. Cytokine IL-6 production inhibition by PEP-1

Test sample		cytokine IL-6 production	
		% of control	inhibition %
PBS		0	-
LPS 1 µg/ml	PBS	100	0
	PEP 1 (5 µg/ml)	28	72

Experiment 2-4. HMGB1, TNF-α, COX-2 expression inhibition

[0096] Protein expression level was determined by Western blot analysis. Cells grown in PEP-1 containing medium were washed with PBS, treated with 0.05% trypsin-EDTA, and collected by centrifugation. The collected cells were dissolved in an appropriate volume of lysis buffer. Intracellular debris was pelleted by centrifugation, and equal amount of protein from each sample was separated by SDS-polyacrylamide gel electrophoresis. The separated protein was transferred to nitrocellulose membrane (Schleicher and Schuell, Keene, NH, USA), then was tested for the antibody specific for each protein.. The membrane was incubated with ECL (enhanced chemiluminescence) solution (Amersham Life Science Corp., Arlington Heights, IL, USA), exposed to X-ray, and the level of protein expression was analyzed according to the exposure level shown on the X-ray film.

[0097] Western blot analysis was performed to determine the inhibitory effect of Ppep1 on the cytokine protein expression. As shown in Table 5 below, stimulation of cells with LPS increased the expression of cytokines; HMGB1, TNF-α and COX. However, if cells were treated with both LPS and Pep1, the expression level of pro-inflammatory cytokines mentioned above decreased. The result showing the treatment with Pep1 decreased pro-inflammatory cytokine levels

by more than 70% provide strong evidence supporting the anti-inflammatory effect of Pep1.

Table 5. The measurement of inhibitory effect of Pep1 on pro-inflammatory cytokine expression level.

Test sample		Cytokine Expression Level (band intensity) % of control		
		HMGB1	TNF- α	COX-2
PBS		-	-	-
LPS 1 μ g/ml	PBS	100	100	100
	PEP 1 (5 μ g/ml)	30	25	22

Experiment 3: Investigation of the inhibitory effect of Pep1 on TNF- α level in HepG2 cells

Experiment 3-1: Cell Culture

[0098] PBMC (peripheral blood mononuclear cell) was separated from the blood samples (50ml) collected from healthy subjects using Ficoll-Paque™ PLUS (GE Healthcare Life Sciences, Piscataway, NJ, USA). PBMCs were then enriched in complete RPMI 1640 medium containing 20% of human serum, followed by transferring to 100mm polystyrene cell culture plate coated with human serum for 30 mins. After 2 hr incubation at 37°C and 5% CO₂, the monocytes were detached from the bottom of cell culture plate using cold PBS (Phosphate Buffered Saline) (Gibco/Life Technologies, Carlsbad, CA, USA), and 1 × 10⁵ cells were cultured in each well of 96-well plate in RPMI 1640 medium (supplemented with penicillin-streptomycin; 100 mg/ml, human serum; 20%) over night.

[0099] For Luciferase Analysis, HEK293/null (human embryonic kidney) cells and HEK293/TRL stably expressing TLR2 (toll-like receptor2) obtained from Seoul National University School of Dental Medicine were used.. One day before the luciferase experiment, 2.5 × 10⁵ cells were seeded into each well of 12-well plate and cultured overnight in DMEM (Dulbecco's modified Eagle's medium) medium (supplemented with blasticidin; 10 μ g/ml, fetal bovine serum; 10%)(Invitrogen/Life Technologies, Carlsbad, CA, USA)

Experiment 3-2: Cytokine Assay

[0100] To see the effect of PEP-1 on TNF- α level in terms of protein expression level, ELISA (enzyme linked immunosorbent assay) was performed. 1 × 10⁵ PBMC-derived monocytes were cultured in 96-well plate over night. After then, LPS (lipopolysaccharide; 10 ng/ml, Sigma) was treated for 2 hours, followed by 3 times washes with PBS. OPTI-MEM medium (Invitrogen/Life Technologies, Carlsbad, CA, USA) was then treated for an hour to induce the starvation, and 4 μ M of FITC (Fluorescein Isothiocyanate), FITC-TAT, PEP-1-FITC, and FITC-PEP-1 were treated for 2 hours before measuring the TNF- α level. After culturing, cell soup was collected, and the amount of TNF- α was measured using ELISA kit (R&D, Minneapolis, MN, USA) as follows:

TNF measurement uses sandwich ELISA method. 100 μ l of TNF- α primary antibody was added into each well of pre-coated 96-well plate, and the plate was incubated at 4°C overnight. On next day, the plate was washed 3 times with 0.5% Tween20 wash solution for 5 min each, and then 100 μ l of each sample and standard solution was added and left at room temperature for 2 hrs. After washing the plate like above, 100 μ l of HRP-conjugated secondary antibody was added into each well and left at room temperature for 2 hrs. Again, plate was washed, and avidin/biotin was added for measuring the absorbance. TNF- α level of each sample was quantified using the standard graph calculated from the absorbance of standard solution.

[0101] PBMC-derived monocytes were stimulated with endotoxin LPS (10ng/ml) for 2hrs, starved for 1hr using OPTI-MEM, and then 4 μ M of FITC, FITC-TAT, PEP 1-FITC and FITC-PEP 1 were treated for 2 hrs. After incubation, TNF- α level was measured with cell culture medium using ELISA. As a result, in case of FITC and FITC-TAT, TNF- α level increased due to LPS (6.2 and 6.7ng/ml, respectively), but TNF- α level significantly decreased in case of PEP-1-FITC and FITC-PEP-1 (0.17 and 0.25 ng/ml, respectively) and the difference was statistically significant (P < 0.01) (FIG. 1).

Experiment 3-3: Luciferase Assay

[0102] To investigate the role of PEP 1 in inflammatory response, we evaluated NF-kB expression patterns through luciferase analysis. First, we incubated HEK293/null and HEK293/TLR2 (Graduate School of Dentistry, Seoul National University) in a 12-well plate for 24 hours, so that we would get 2.5 × 10⁵ cells/well. After washing three times with PBS, medium was replaced with OPTI-MEM (Invitrogen/Life Technologies, Carlsbad, CA, USA) and incubated for 4 hours, and then a mixture of 3 μ l lipofectamine (Invitrogen/Life Technologies), 1 μ g NF-kB luciferase and 10ng renilla luciferase

(Promega, Madison, WI, USA) was added into each well and again incubated for 4 hours. Lipoprotein pam3cys (10ng/ml, Sigma-Aldrich, St. Louis, MO, USA) was put into all of the wells except for those of negative control, and FITC (4 μ M) and FITC-PEP 1 (4 μ M) were treated for 18 hours before it was washed with PBS for three times. We confirmed the activation of NF-kB through TD-20/20 luminometer (Turner designs, Sunnyvale, CA, USA) after dissolving (lysis) of cells by putting 50 μ l of passive lysis buffer - provided by dual-luciferase reporter assay system (Promega) - into each well. Transfection efficacy was confirmed by cotransfection of pCMV-renilla luciferase(Promega), and we analyzed results by calibrating the luciferase values.

[0103] After transfecting NF-kB luciferase to HEK293/null and HEK293/TLR2 cell lines, pam3cys, a synthetic lipoprotein, and FITC (4 μ M), a negative control were treated together, and pam3cys with FITC-PEP 1 (4 μ M) were again treated together to be cultured for 18 hours. The measurement of NF-kB expression patterns by luciferase strength through lysis of cells with passive lysis buffer - provided by dual-luciferase reporter assay system (Promega)-showed that there was no difference in lipoprotein or FITC-PEP1 treated or non-treated HEK293/null. However, when lipoprotein, an agonist of TLR2, was treated to HEK293/TLR2 cell line, NF-kB expression increased ($P<0.01$) compared to that in untreated, confirming occurrence of inflammatory responses. Also, NF-kB expression increased when FITC-PEP 1 was treated together compared to that in untreated; and expression decreased compared to the negative control in which lipoprotein and FITC were treated together ($P<0.01$) (FIG.2). Ultimately, we were able to confirm that inflammatory response that can be caused by TLR 2 is reduced when PEP 1 is treated together.

EXAMPLE 2

TNF- α inhibitory effect of PEP RIA series (SEQ ID NO: 2 to 179) peptides

[0104] Based on the results from Example 1 in which the SEQ ID NO: 1 (PEP1) has the TNF- α inhibitory effect, experiment using peptides SEQ ID NO: 2 to 179 were carried out to confirm their TNF- α inhibitory effect. The synthesis of peptides SEQ ID NO: 2 to 179 used the same method mentioned above in Example 1 (method used for synthesis of PEP1), but the amino acids added were different.

Experiment 1: cell culture

[0105] PBMC (peripheral blood mononuclear cells) layer was separated from blood samples (50 ml) collected in healthy subjects using Biocoll Separating Solution (Biochrom AG, Berlin, Germany). The collected PBMC were enriched in RPMI 1640 medium containing 20% human serum for 30 mins, and then transferred to 100-mm polystyren cell culture plate coated with human serum for incubation for 2 hrs at 37°C, 5% CO₂ incubator. Monocytes were detached from the bottom of the plate using cold PBS, and incubated to reach the number of 1×10^5 cell/well in 96-well plate with RPMI 1640 medium (supplemented with penicillin-streptomycin; 100 mg/ml, human serum; 20%) over night.

Experiment 2: Analysis of TNF- α inhibitory effect

[0106] ELISA was performed to find out how the peptides of the PEP RIA series influence TNF- α level. PBMC-derived monocytes were incubated to reach the number of 1×10^5 cells per well in a 96-well plate and then treated with LPS (lipopolysaccharide; 10 ng/ml, Sigma) for 2 hours. To the monocytes that were washed three times with PBS, OPTI-MEM culture medium was added to induce cell starvation for an hour, 4 μ M of the peptide was taken out and incubated for 2 hours. There were three negative control groups. The first group was not treated with anything. The second group that was treated with estrogen (in this experiment, estradiol was used as a kind of estrogen). The third group was treated with LPS (10 ng/ml) or with LPS (10 ng/ml) as well as estrogen (20 nM). PEP1 that was confirmed to have TNF- α inhibiting activity was used as a positive control to measure TNF- α inhibiting activity. After incubation, TNF- α was measured by following the ELISA kit manual (R&D, Minneapolis, MN, USA). The details of quantification method can be found in Experiment 2.2 of Example 1.

[0107] Using the method stated above, Peptides with TNF- α inhibiting effect were screened. PBMC-derived monocytes were stimulated with LPS (10 ng/ml), which is endotoxin, for 2 hours and were induced to starve by adding OPTI-MEM for 1 hour. After that, 4 μ M of 179 peptides were treated and incubated for 2hrs. The amount of TNF- α in the cell culture medium was measured using ELISA, and the peptides with TNF- α inhibiting effect were screened by comparing to the negative and positive controls (FIG. 3 to FIG. 23).

[0108] The followings are the peptide sequences that showed TNF- α inhibiting effect when compared to the control group that was treated with only LPS: SEQ ID NO: 9, SEQ ID NO:10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 54, SEQ ID NO: 55,

SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 105, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 124, SEQ ID NO: 131, SEQ ID NO: 140, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 150, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 159, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, and SEQ ID NO: 178.

[0109] Also, the followings are the peptide sequences that showed TNF- α inhibiting effect when compared to the group treated with LPS and estrogen: SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 70, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 73, SEQ ID NO: 80, SEQ ID NO: 81, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 96, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99, SEQ ID NO: 100, SEQ ID NO: 101, SEQ ID NO: 102, SEQ ID NO: 103, SEQ ID NO: 108, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 140, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 156, SEQ ID NO: 157, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 174.

Experiment 3: Analysis of peptides affecting TNF- α level in THP1 cell line

[0110] Experiment was carried out using THP-1 cell line (American Type Culture Collection (ATCC), Manassas, VA, USA) which is human acute monocytic leukemia.

[0111] THP-1 cells were incubated to reach the number of 1×10^5 cells per well in a 96-well plate with RPMI 1640 medium for 24 hrs, followed by addition of 100 μ M of PMA (phorbol 12-myristate 13-acetate) for the differentiation into macrophage. After differentiation of THP-1 into macrophage by PMA for a day, LPS was treated for 2hrs and washed off. Starvation for an hour and PEP1 treatment followed.

[0112] THP-1 cell differentiated by PMA was treated with LPS (lipopolysaccharide; 10 ng/ml, Sigma) for 2 hours, followed by 2 times washes with PBS. To the cells, OPTI-MEM culture medium was added to induce cell starvation for an hour, and 1 μ M of 179 peptides was taken out and incubated for an hour. After incubation, TNF- α level was measured by using the ELISA kit and the peptides which reduce the TNF- α level were screened (Figure 24 to Figure 46).

[0113] As a result, peptide sequence SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 78, SEQ ID NO: 107, SEQ ID NO: 109 and SEQ ID NO: 179 appeared to reduce the TNF- α level compared to control group treated only with LPS. In addition, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 30, SEQ ID NO: 41, SEQ ID NO: 112 and SEQ ID NO: 113 were selected as peptides which reduce the expression level of TNF- α compared to that of group treated with LPS and estrogen.

EXAMPLE 3

Analysis of inflammatory response induced by amyloid- β protein

[0114] HMGB1 first undergoes acetylation and translocation to cytoplasm by external stimulation. Then it is secreted out of the cell, therefore serving the role of inflammation-causing cytokine. Because when one has an inflammation due to such activity, HMGB1 protein is secreted from the cell, and patients with inflammatory diseases such as Churg Strauss syndrome, rheumatoid arthritis and Sjogren's syndrome will present with elevated serum levels of HMGB1. Hence, if nucleus contains large amount of HMGB1 even when there is a stimulus that causes inflammation, it is suggestive of the fact that HMGB1 is not being secreted out of the cell, which means inflammation is being suppressed.

Experiment 1: Analysis of survival and proliferation of neural stem cells by anti-inflammatory effects of PEP-1

[0115] First of all, PEP-1 was prepared according to the manufacturing methods described in Example 1.

Experiment 1-1: Neural stem cell culture and Amyloid- β toxicity assessment

[0116] After removing the cortex from the head of an embryonic rat that had been pregnant for 13 days, it was cultured for a week with Basic Fibroblast Growth Factor (bFGF) to obtain the neural stem cells. To analyze the effects of the

amyloid- β protein on the neural stem cells, the pre-oligomerized amyloid- β protein of concentrations 0 to 40 μ M was treated on neural stem cells for 48 hours, then CCK-8 assay, BrdU, and TUNEL assay were used for cytotoxicity assessment (refer from BA Yankner *et al*, 1990 and KN Dahlgren *et al*, 2002). We used the same concentration of amyloid- β protein in subsequent experiments after we confirmed that cell survival was reduced to 60% when processed with 20 μ M of amyloid- β protein (Refer to FIG. 47 and 48).

Experiment 1-2: Cell toxicity assessment by treatment with PEP-1

[0117] To evaluate the impact of PEP-1 on the cultured neural stem cells, the neural stem cells were firstly cultured by a well-known method (BA Yankner *et al*, 1990 and KN Dahlgren *et al*, 2002). Then, different concentrations (0, 1, 10, 50, 100, 200 μ M) of PEP-1 were treated for 48 hours, followed by cell viability and proliferation assessments using MTT assay, BrdU and TUNEL assay. PEP-1's concentrations from 0 to 200 μ M appeared stable in the neuronal system since they did not inhibit both survival and proliferation of neural stem cells (Refer to FIG. 49 and 50).

Experiment 1-3: Cell toxicity assessment by co-treatment of amyloid- β protein and telomerase peptide

[0118] To determine whether PEP 1 has the effect of suppressing the neurotoxicity caused by amyloid- β protein, 20 μ M amyloid- β protein and various concentrations of PEP-1 were co-treated for 48 hours. The cell viability and apoptosis were measured using MMT assay, CCK-8 assay, LDH assay and TUNEL assay, and neural stem cell proliferation by BrdU assay.

[0119] The results of MMT assay and CCK-8 assay confirmed that 10 μ M of PEP-1 began to protect neural stem cells from neurotoxicity by amyloid- β , and the most effective protection was provided in 100 μ M. (Refer to FIG. 51). LDH assay was carried out for assessment of the degree of cell death as another method, and we confirmed that the increase in cell death by amyloid- β decreased by PEP-1, and efficacy was seen starting at 1 μ M concentration (Refer to FIG. 52).

[0120] We also confirmed with BrdU assay that the decreased cell proliferation due to amyloid- β protein was restored when processed with PEP-1 (Refer to FIG. 53).

[0121] Cell mobility is a vital matter due to the nature of neural stem cell. According to the experimental results of cell mobility, we confirmed that the decreased cell proliferation due to amyloid- β protein was restored when processed with PEP-1, and that it increased even more when in 10 μ M concentration, compared to control. This suggests that in the future clinical trials, processing prior to stem cell transplantation may draw more effective results. (Refer to FIG. 54).

[0122] To confirm the degree of neuronal stem cells damage, TUNEL assay was performed. Neuronal stem cell death was observed to be significantly increased in 20 μ M amyloid- β protein treatment group, and neuronal stem cell death decreased when treated with 1 to 100 μ M of PEP 1. (Refer to FIG. 55)

The mechanism of action of PEP-1's protective effect on apoptosis by amyloid- β protein was investigated. First, it was investigated whether PEP-1 is capable of minimizing the oxidative damage caused by amyloid- β protein. Change in generation of reactive oxygen species after treatment with amyloid- β protein and PEP-1 was observed by using DCF-DA staining (Molecular Probes, Eugene, OR). In the group in which reactive oxygen species increased due to 20 μ M of amyloid- β protein, the increased reactive oxygen species decreased by PEP-1 treatment (1 μ M, 10 μ M, 50 μ M) (Refer to FIG. 56).

Experiment 1-4: Comparative analysis of protein expression levels between the groups treated with and without PEP-1

[0123] Protein expression level of PEP-1 treated group and untreated group was analyzed by 2D-electrophoresis technique and antibody microarray technique. Prepared 200 μ g by extracting proteome from the neural stem cells cultured in Experiment 1-1 of example 3. In addition, the group in which PEP-1 was not treated was used as the comparison group in the same condition.

[0124] 2D-electrophoresis was performed using 12% acrylamide gels. First gel electrophoresis was performed at PI 4~10N, using a gel size of 8.5x7cm. After electrophoresis, it was dyed with Colloidal Coomassie Blue, and then compared expression by using PDQuest software to analyze each spot.

[0125] Difference in the expression levels of more than 1.5 times was identified using MALDI-TOF MS (Matrix Desorption/Ionization Time of Flight Mass Spectrometry). Among these, proteins correlated with inflammation-related signaling, such as i-NOS and HMGB-1 were identified (Refer to Table 6). The changes in protein expression levels either increased or decreased by 1.5 times by amyloid- β protein, but it was confirmed that expression level was regulated close to that of negative control when PEP-1 was added (Refer to FIG. 57).

[0126] Antibody microarray was carried out by using cell signaling kit (CSAA1, PanoramaTM Ab Microarray Cell Signaling kit), array slides were scanned by GenePix Personal 4100A scanner (Molecular Devices) and the data were analyzed by GenePix Pro 5.0 (Molecular Devices).

[0127] The Table 6 below is an analysis of expression levels of proteins associated with inflammation by 2D electro-

phoresis technique. The control group represents protein expression level of cells that were not treated with neither amyloid- β protein nor PEP-1. It shows increased or decreased multiple of protein expression based on the control group's expression level.

[0128] We confirmed with the results of analysis that like the suggested in Table 6 below, inflammation related protein over-expression or under-expression was controlled by PEP-1; the protein expression level was close to that of negative control group.

Table 6

Protein	Negative Control	20ug β -amyloid treated group (fold)	20ug β -amyloid+PEP 1 treated group (fold)
HSP 70	1.0	-2.3	1.2
HSP 90	1.0	-1.8	1.0
HHGB1	1.0	-1.5	2.8
GADD 153	1.0	1.6	1.2
i-NOS	1.0	1.9	-1.1
e-NOS	1.0	1.9	-1.1
Pyk2	1.0	2.0	1.2
MAP Kinase	1.0	2.2	1.0

[0129] Phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway serves a crucial role in the growth and survival of neuronal stem cells. PI3K pathway is activated by growth factors and regulatory factors, and is involved in the normal regulation of neuronal stem cell growth and survival. AKT signaling pathways disable several pro-apoptotic factors, including a well-known apoptotic signaling molecule, GSK3 β .

[0130] To further investigate the anti-inflammatory effects of PEP-1, we performed Western blot on HMGB1, since it showed a major change in protein analysis. As a result, the processing of the PEP-1 increased the protein expression levels in anti-apoptotic proteins such as Ki67, pAKT, PI3K, HSTF-1 and Bcl-2, and decreased the protein expression levels of apoptotic signals such as Bax, GSK3 β , Cytochrom-c, caspase-3 (Refer to FIG. 58).

[0131] HMGB1, a non-histone structure protein that binds to DNA, serves diverse roles within a cell; such as stabilizing nucleosome structure and regulating gene expression. As one of the inflammation-causing substance that is excreted in the late phase of inflammatory response, it is excreted by macrophages and monocytes when inflammation is stimulated, but when neuron is significantly damaged and leads to cell necrosis, it will be excreted out of the cell, causing an intense inflammatory response. The increase of HMGB1 by PEP-1 treatment after the decrease by amyloid- β treatment in the cytoplasm of the nerve cells reflects the fact that PEP-1 inhibits secretion of HMGB1 out of the cell caused by neuron cell death; therefore suggesting that PEP-1 has powerful anti-inflammatory effects (Refer to FIG. 58).

[0132] In addition, we investigated the response of PEP-1 to the amyloid- β aggregation. Aggregation of protein was inhibited when treated with PEP-1 (Refer to FIG. 59 (A)) in induction of aggregation of amyloid- β , and protein underwent degradation when PEP-1 was treated on the amyloid- β protein that was already induced for aggregation (Refer to FIG. 59(B)).

[0133] In the mechanism of action of PEP-1, we have previously confirmed the increase in cell survival signaling and decrease in apoptosis signaling of PI3K. To investigate whether these effects are direct or indirect, we treated PI3K-inhibitor, LY294002 (Promega). As a result, the increased cell viability after treating with PEP 1 decreased when treated with LY294002. Thus, we can conclude that PI3K is directly associated with PEP 1's neuroprotective effect (Refer to FIG. 60).

[0134] PEP-1 inhibits apoptosis of neural stem cells by amyloid- β protein. Also, the improvement of cell mobility of neural stem cells was confirmed, therefore suggesting a variety of possibilities in clinical application. The inhibition effects from neurotoxicity caused by beta-amyloid protein was verified by the anti-inflammatory effect of the mechanism of action of PEP 1, increased survival factors of neuro stem cells and decreased apoptotic factors, especially activation of PI3K signaling pathway and antioxidant effects.

EXAMPLE 4

Effects of PEP RIA series' peptides (Sequence No.2 to 179) on inflammation by amyloid- β protein

5 Experiment 1. Cell culture

[0135] Undifferentiated PC12 cells (ATCC, Rockville, MD, USA) were maintained in logarithmic-phase growth on poly-L-lysine (Sigma, Saint Louis, MO, USA) - pre-coated 100mm dishes (Corning, PA, USA) in RPMI 1640 medium (GIBCO, Grand Island, NY, USA) containing 10% heat-inactivated horse serum, 5% heat-inactivated fetal bovine serum, 100 units/ml penicillin, and 100g/ml streptomycin. Cultures were incubated at 37°C in a humidified atmosphere with 5% CO₂. The cultures were grown to 50% confluence and were harvested in Ca²⁺/Mg²⁺- free Hank's balanced salt solution containing 1mM EDTA. Cells were plated at a density of 1×10⁶ cells/100mm dish and incubated for 24 hrs. For neuronal differentiation, PC12 cells were serum-starved for 12 hrs (RPMI1640 medium containing 100 units/ml penicillin and 100g/ml streptomycin without horse serum or fetal bovine serum); thereafter, the cells were maintained in serum-free medium. After two days the medium was replaced with fresh serum-free medium. On day three, NGF (50 ng/ml, Sigma, Saint Louis, MO, USA) was added to the medium, and the cultures were maintained for an additional three days. After differentiation, nPC12 cells were incubated with 20μM amyloid- β with several concentrations of peptides [0 (control), 1, 10, and 50 μM] for 48 hrs.

20 Experiment 2. Western blot analysis

[0136] Levels of HMGB1 were analyzed by western blotting. Briefly, 5 X 10⁶ cells were washed twice in cold PBS, incubated for 10 min on ice in lysis buffer [50 mM Tris (pH 8.0), 150 mM NaCl, 0.02% sodium azide, 0.2% SDS, 100 μg/ml phenyl methyl sulfonyl fluoride (PMSF), 50 μl/ml aprotinin, 1% Igepal 630, 100 mM NaF, 0.5% sodium deoxy choate, 0.5 mM EDTA, 0.1 mM EGTA]; unbroken cells and nuclei were pelleted by centrifugation for 10 min at 2000 × g and the lysates were cleared by centrifugation at 10,000 × g. The antibodies used were: anti-HMGB1 (1:1000, Cell Signaling, Beverly, MA, USA) and anti- β -tubulin (1:1000, Cell Signaling, Beverly, MA, USA). The membranes were washed with Tris-buffered saline containing 0.05% Tween-20 (TBST), and then processed using HRP-conjugated anti-rabbit antibody (Amersham Pharmacia Biotech, Piscataway, NJ, USA) followed by ECL detection (Amersham Pharmacia Biotech.). The blots were quantified with an image analyzer (GE Healthcare, ImageQuant LAS 4000).

[0137] As a result of the western blot analysis, peptides showing accumulation of HMGB1 in the cell were selected. FIG 60 to FIG. 159 are the western blot results of selected peptides. Tubulins in these figures are used for confirming protein expression. The sequences of the selected peptides are as follows:

SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 61, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 73, SEQ ID NO: 74, SEQ ID NO: 75, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95, SEQ ID NO: 96, SEQ ID NO: 98, SEQ ID NO: 102, SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117, SEQ ID NO: 118, SEQ ID NO: 119, SEQ ID NO: 120, SEQ ID NO: 121, SEQ ID NO: 123, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 130, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 147, SEQ ID NO: 148, SEQ ID NO: 149, SEQ ID NO: 153, SEQ ID NO: 154, SEQ ID NO: 155, SEQ ID NO: 157, SEQ ID NO: 158, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 172, SEQ ID NO: 173, SEQ ID NO: 175, SEQ ID NO: 176, SEQ ID NO: 177, SEQ ID NO: 178, and SEQ ID NO: 179.

50 SEQUENCE LISTING

[0138]

<110> Kael-GemVax Co., Ltd GemVax AS KIM, Sang Jae

<120> ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAME

<130> 19620PCT00

EP 2 850 097 B1

<150> KR 10-2012-0050529
 <151> 2012-05-11

 <150> KR 10-2012-0050533
 <151> 2012-05-11

 <150> KR 10-2012-0071989
 <151> 2012-07-02

 <150> KR 10-2012-0104144
 <151> 2012-09-19

 <150> KR 10-2012-0104207
 <151> 2012-09-19

 <160> 180

 <170> PatentIn version 3.5

 <210> 1
 <211> 16
 <212> PRT
 <213> Homo sapiens

 <400> 1

 Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
 1 5 10 15

 <210> 2
 <211> 17
 <212> PRT
 <213> Homo sapiens

 <400> 2

 Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro
 1 5 10 15

 Lys

 <210> 3
 <211> 18
 <212> PRT
 <213> Homo sapiens

 <400> 3

 His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile

 1 5 10 15

 Pro Lys

 <210> 4

EP 2 850 097 B1

<211> 19
 <212> PRT
 <213> Homo sapiens

5 <400> 4

Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe
 1 5 10 15

10 Ile Pro Lys

<210> 5
 <211> 20
 <212> PRT
 <213> Homo sapiens

15 <400> 5

20 Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg
 1 5 10 15

25 Phe Ile Pro Lys
 20

<210> 6
 <211> 21
 <212> PRT
 <213> Homo sapiens

30 <400> 6

35 Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu
 1 5 10 15

40 Arg Phe Ile Pro Lys
 20

<210> 7
 <211> 22
 <212> PRT
 <213> Homo sapiens

45 <400> 7

Glu Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg
 1 5 10 15

50 Leu Arg Phe Ile Pro Lys
 20

<210> 8
 <211> 23
 <212> PRT
 <213> Homo sapiens

55

EP 2 850 097 B1

<400> 8

Ala Glu Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser
1 5 10 15

Arg Leu Arg Phe Ile Pro Lys
20

<210> 9
<211> 24
<212> PRT
<213> Homo sapiens

<400> 9

Glu Ala Glu Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr
1 5 10 15

Ser Arg Leu Arg Phe Ile Pro Lys
20

<210> 10
<211> 25
<212> PRT
<213> Homo sapiens

<400> 10

Ser Glu Ala Glu Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu
1 5 10 15

Thr Ser Arg Leu Arg Phe Ile Pro Lys
20 25

<210> 11
<211> 26
<212> PRT
<213> Homo sapiens

<400> 11

Leu Ser Glu Ala Glu Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu
1 5 10 15

Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
20 25

<210> 12
<211> 27
<212> PRT
<213> Homo sapiens

<400> 12

EP 2 850 097 B1

	Glu	Leu	Ser	Glu	Ala	Glu	Val	Arg	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	
	1				5					10					15		
5		Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile	Pro	Lys					
					20					25							
	<210> 13																
	<211> 28																
10	<212> PRT																
	<213> Homo sapiens																
	<400> 13																
15		Arg	Glu	Leu	Ser	Glu	Ala	Glu	Val	Arg	Gln	His	Arg	Glu	Ala	Arg	Pro
		1				5					10					15	
		Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile	Pro	Lys				
20					20					25							
	<210> 14																
	<211> 29																
	<212> PRT																
25	<213> Homo sapiens																
	<400> 14																
30		Leu	Arg	Glu	Leu	Ser	Glu	Ala	Glu	Val	Arg	Gln	His	Arg	Glu	Ala	Arg
		1				5					10					15	
		Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile	Pro	Lys			
35					20					25							
	<210> 15																
	<211> 30																
	<212> PRT																
	<213> Homo sapiens																
40	<400> 15																
		Gln	Leu	Arg	Glu	Leu	Ser	Glu	Ala	Glu	Val	Arg	Gln	His	Arg	Glu	Ala
45		1				5					10					15	
		Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile	Pro	Lys		
					20					25					30		
50	<210> 16																
	<211> 18																
	<212> PRT																
	<213> Homo sapiens																
55	<400> 16																

EP 2 850 097 B1

Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro
1 5 10 15

5 Lys Pro

<210> 17

<211> 19

<212> PRT

10 <213> Homo sapiens

<400> 17

15 His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile
1 5 10 15

Pro Lys Pro

20 <210> 18

<211> 20

<212> PRT

<213> Homo sapiens

25 <400> 18

His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile
1 5 10 15

30 Pro Lys Pro Asp
20

<210> 19

35 <211> 19

<212> PRT

<213> Homo sapiens

<400> 19

40 Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro
1 5 10 15

45 Lys Pro Asp

<210> 20

<211> 20

<212> PRT

50 <213> Homo sapiens

<400> 20

55

EP 2 850 097 B1

	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe
	1				5					10					15	

5	Ile	Pro	Lys	Pro												
				20												

	<210>	21
	<211>	21
10	<212>	PRT
	<213>	Homo sapiens
	<400>	21

15	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe
	1				5					10					15	

	Ile	Pro	Lys	Pro	Asp											
20				20												

	<210>	22
	<211>	22
	<212>	PRT
25	<213>	Homo sapiens
	<400>	22

30	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe
	1				5					10					15	

	Ile	Pro	Lys	Pro	Asp	Gly										
35				20												

	<210>	23
	<211>	21
	<212>	PRT
	<213>	Homo sapiens
40	<400>	23

	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile
45	1				5					10					15	

	Pro	Lys	Pro	Asp	Gly											
				20												

50	<210>	24
	<211>	20
	<212>	PRT
	<213>	Homo sapiens
55	<400>	24

	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile	Pro
--	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

EP 2 850 097 B1

1 5 10 15

5 Lys Pro Asp Gly
20

<210> 25

<211> 21

<212> PRT

10 <213> Homo sapiens

<400> 25

15 Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg
1 5 10 15

Phe Ile Pro Lys Pro
20

20

<210> 26

<211> 22

<212> PRT

<213> Homo sapiens

25

<400> 26

30 Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg
1 5 10 15

30

Phe Ile Pro Lys Pro Asp
20

35

<210> 27

<211> 23

<212> PRT

<213> Homo sapiens

40

<400> 27

Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg
1 5 10 15

45

Phe Ile Pro Lys Pro Asp Gly
20

<210> 28

50

<211> 24

<212> PRT

<213> Homo sapiens

<400> 28

55

Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg
1 5 10 15

EP 2 850 097 B1

Phe Ile Pro Lys Pro Asp Gly Leu
20

5 <210> 29
<211> 23
<212> PRT
<213> Homo sapiens

10 <400> 29

Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe
1 5 10 15

15 Ile Pro Lys Pro Asp Gly Leu
20

20 <210> 30
<211> 22
<212> PRT
<213> Homo sapiens

<400> 30

25 His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile
1 5 10 15

30 Pro Lys Pro Asp Gly Leu
20

<210> 31
<211> 21
<212> PRT
35 <213> Homo sapiens

<400> 31

40 Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro
1 5 10 15

45 Lys Pro Asp Gly Leu
20

<210> 32
<211> 22
<212> PRT
50 <213> Homo sapiens

<400> 32

55 Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu
1 5 10 15

Arg Phe Ile Pro Lys Pro
20

EP 2 850 097 B1

<210> 33
 <211> 23
 <212> PRT
 <213> Homo sapiens
 5
 <400> 33
 Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu
 1 5 10 15
 Arg Phe Ile Pro Lys Pro Asp
 20
 15
 <210> 34
 <211> 24
 <212> PRT
 <213> Homo sapiens
 20
 <400> 34
 Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu
 1 5 10 15
 25
 Arg Phe Ile Pro Lys Pro Asp Gly
 20
 30
 <210> 35
 <211> 25
 <212> PRT
 <213> Homo sapiens
 35
 <400> 35
 Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu
 1 5 10 15
 40
 Arg Phe Ile Pro Lys Pro Asp Gly Leu
 20 25
 45
 <210> 36
 <211> 26
 <212> PRT
 <213> Homo sapiens
 <400> 36
 50
 Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu
 1 5 10 15
 55
 Arg Phe Ile Pro Lys Pro Asp Gly Leu Arg
 20 25
 <210> 37
 <211> 25

EP 2 850 097 B1

<212> PRT

<213> Homo sapiens

<400> 37

5

Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg
1 5 10 15

10

Phe Ile Pro Lys Pro Asp Gly Leu Arg
20 25

<210> 38

<211> 24

15

<212> PRT

<213> Homo sapiens

<400> 38

20

Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe
1 5 10 15

25

Ile Pro Lys Pro Asp Gly Leu Arg
20

<210> 39

<211> 23

<212> PRT

30

<213> Homo sapiens

<400> 39

35

His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile
1 5 10 15

40

Pro Lys Pro Asp Gly Leu Arg
20

<210> 40

<211> 22

<212> PRT

<213> Homo sapiens

45

<400> 40

50

Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro
1 5 10 15

Lys Pro Asp Gly Leu Arg
20

55

<210> 41

<211> 23

<212> PRT

<213> Homo sapiens

EP 2 850 097 B1

<400> 41

5 Glu Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg
 1 5 10 15

 Leu Arg Phe Ile Pro Lys Pro
 20

10 <210> 42
 <211> 24
 <212> PRT
 <213> Homo sapiens

15 <400> 42

 Glu Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg
 1 5 10 15

20 Leu Arg Phe Ile Pro Lys Pro Asp
 20

25 <210> 43
 <211> 25
 <212> PRT
 <213> Homo sapiens

30 <400> 43

 Glu Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg
 1 5 10 15

35 Leu Arg Phe Ile Pro Lys Pro Asp Gly
 20 25

40 <210> 44
 <211> 26
 <212> PRT
 <213> Homo sapiens

<400> 44

45 Glu Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg
 1 5 10 15

50 Leu Arg Phe Ile Pro Lys Pro Asp Gly Leu
 20 25

55 <210> 45
 <211> 27
 <212> PRT
 <213> Homo sapiens

<400> 45

EP 2 850 097 B1

Glu Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg

5 1 5 10 15

Leu Arg Phe Ile Pro Lys Pro Asp Gly Leu Arg
 20 25

10 <210> 46
 <211> 28
 <212> PRT
 <213> Homo sapiens

15 <400> 46

Glu Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg
1 5 10 15

20 Leu Arg Phe Ile Pro Lys Pro Asp Gly Leu Arg Pro
 20 25

25 <210> 47
 <211> 27
 <212> PRT
 <213> Homo sapiens

30 <400> 47

Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu
1 5 10 15

35 Arg Phe Ile Pro Lys Pro Asp Gly Leu Arg Pro
 20 25

40 <210> 48
 <211> 26
 <212> PRT
 <213> Homo sapiens

45 <400> 48

Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg
1 5 10 15

50 Phe Ile Pro Lys Pro Asp Gly Leu Arg Pro
 20 25

55 <210> 49
 <211> 25
 <212> PRT
 <213> Homo sapiens

 <400> 49

EP 2 850 097 B1

Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe
1 5 10 15

Ile Pro Lys Pro Asp Gly Leu Arg Pro
20 25

<210> 50

<211> 24

<212> PRT

<213> Homo sapiens

<400> 50

His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile
1 5 10 15

Pro Lys Pro Asp Gly Leu Arg Pro
20

<210> 51

<211> 23

<212> PRT

<213> Homo sapiens

<400> 51

Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro
1 5 10 15

Lys Pro Asp Gly Leu Arg Pro
20

<210> 52

<211> 24

<212> PRT

<213> Homo sapiens

<400> 52

Ala Glu Val Arg Gln His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser
1 5 10 15

Arg Leu Arg Phe Ile Pro Lys Pro
20

<210> 53

<211> 25

<212> PRT

<213> Homo sapiens

<400> 53

EP 2 850 097 B1

	Ala	Glu	Val	Arg	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser
	1				5					10					15	
5	Arg	Leu	Arg	Phe	Ile	Pro	Lys	Pro	Asp							
				20					25							
	<210> 54															
	<211> 26															
10	<212> PRT															
	<213> Homo sapiens															
	<400> 54															
15	Ala	Glu	Val	Arg	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser
	1				5					10					15	
	Arg	Leu	Arg	Phe	Ile	Pro	Lys	Pro	Asp	Gly						
20				20					25							
	<210> 55															
	<211> 27															
	<212> PRT															
25	<213> Homo sapiens															
	<400> 55															
30	Ala	Glu	Val	Arg	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser
	1				5					10					15	
	Arg	Leu	Arg	Phe	Ile	Pro	Lys	Pro	Asp	Gly	Leu					
35				20					25							
	<210> 56															
	<211> 28															
	<212> PRT															
	<213> Homo sapiens															
40	<400> 56															
	Ala	Glu	Val	Arg	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser
45	1				5					10					15	
	Arg	Leu	Arg	Phe	Ile	Pro	Lys	Pro	Asp	Gly	Leu	Arg				
				20					25							
50	<210> 57															
	<211> 29															
	<212> PRT															
	<213> Homo sapiens															
55	<400> 57															

EP 2 850 097 B1

	Ala	Glu	Val	Arg	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser
	1				5					10					15	
5	Arg	Leu	Arg	Phe	Ile	Pro	Lys	Pro	Asp	Gly	Leu	Arg	Pro			
				20					25							
	<210> 58															
	<211> 30															
10	<212> PRT															
	<213> Homo sapiens															
	<400> 58															
15	Ala	Glu	Val	Arg	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser
	1				5					10					15	
	Arg	Leu	Arg	Phe	Ile	Pro	Lys	Pro	Asp	Gly	Leu	Arg	Pro	Ile		
20				20					25					30		
	<210> 59															
	<211> 29															
	<212> PRT															
25	<213> Homo sapiens															
	<400> 59															
30	Glu	Val	Arg	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg
	1				5					10					15	
	Leu	Arg	Phe	Ile	Pro	Lys	Pro	Asp	Gly	Leu	Arg	Pro	Ile			
35				20					25							
	<210> 60															
	<211> 28															
	<212> PRT															
	<213> Homo sapiens															
40	<400> 60															
	Val	Arg	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu
45	1				5					10					15	
	Arg	Phe	Ile	Pro	Lys	Pro	Asp	Gly	Leu	Arg	Pro	Ile				
				20					25							
50	<210> 61															
	<211> 27															
	<212> PRT															
	<213> Homo sapiens															
55	<400> 61															

EP 2 850 097 B1

	Arg	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg
	1				5					10					15	
5	Phe	Ile	Pro	Lys	Pro	Asp	Gly	Leu	Arg	Pro	Ile					
				20					25							
	<210> 62															
	<211> 26															
10	<212> PRT															
	<213> Homo sapiens															
	<400> 62															
15	Gln	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe
	1				5					10					15	
	<210> 63															
	<211> 25															
	<212> PRT															
20	<213> Homo sapiens															
	<400> 63															
	Ile	Pro	Lys	Pro	Asp	Gly	Leu	Arg	Pro	Ile						
				20					25							
	<210> 63															
	<211> 25															
	<212> PRT															
25	<213> Homo sapiens															
	<400> 63															
	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile
30	1				5					10					15	
	<210> 64															
	<211> 24															
	<212> PRT															
35	<213> Homo sapiens															
	<400> 64															
	Pro	Lys	Pro	Asp	Gly	Leu	Arg	Pro	Ile							
				20					25							
	<210> 64															
	<211> 24															
	<212> PRT															
40	<213> Homo sapiens															
	<400> 64															
	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile	Pro
45	1				5					10					15	
	<210> 65															
	<211> 17															
	<212> PRT															
50	<213> Homo sapiens															
	<400> 65															
	Lys	Pro	Asp	Gly	Leu	Arg	Pro	Ile								
				20												
	<210> 65															
	<211> 17															
	<212> PRT															
55	<213> Homo sapiens															
	<400> 65															

EP 2 850 097 B1

Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
1 5 10 15

5 Pro

<210> 66

<211> 18

<212> PRT

10 <213> Homo sapiens

<400> 66

15 Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys

1

5

10

15

20 Pro Asp

<210> 67

<211> 19

<212> PRT

25 <213> Homo sapiens

<400> 67

30 Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
1 5 10 15

Pro Asp Gly

35 <210> 68

<211> 21

<212> PRT

<213> Homo sapiens

40 <400> 68

Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
1 5 10 15

45

Pro Asp Gly Leu Arg
20

<210> 69

50 <211> 22

<212> PRT

<213> Homo sapiens

<400> 69

55

EP 2 850 097 B1

Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
 1 5 10 15

 5 Pro Asp Gly Leu Arg Pro
 20

 <210> 70
 <211> 23
 10 <212> PRT
 <213> Homo sapiens

 <400> 70

 15 Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
 1 5 10 15

 Pro Asp Gly Leu Arg Pro Ile
 20
 20

 <210> 71
 <211> 24
 <212> PRT
 25 <213> Homo sapiens

 <400> 71

 30 Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
 1 5 10 15

 Pro Asp Gly Leu Arg Pro Ile Val
 20
 35
 <210> 72
 <211> 25
 <212> PRT
 <213> Homo sapiens
 40
 <400> 72

 Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
 1 5 10 15
 45

 Pro Asp Gly Leu Arg Pro Ile Val Asn
 20 25

 50 <210> 73
 <211> 26
 <212> PRT
 <213> Homo sapiens

 55 <400> 73

EP 2 850 097 B1

	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile	Pro	Lys
	1				5					10					15	
5	Pro Asp Gly Leu Arg Pro Ile Val Asn Met															
					20					25						
	<210> 74															
	<211> 27															
10	<212> PRT															
	<213> Homo sapiens															
	<400> 74															
15	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile	Pro	Lys
	1				5					10					15	
	Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp															
20					20					25						
	<210> 75															
	<211> 28															
	<212> PRT															
25	<213> Homo sapiens															
	<400> 75															
30	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile	Pro	Lys
	1				5					10					15	
	Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr															
35					20					25						
	<210> 76															
	<211> 29															
	<212> PRT															
	<213> Homo sapiens															
40	<400> 76															
45	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile	Pro	Lys
	1				5					10					15	
	Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val															
					20					25						
50	<210> 77															
	<211> 30															
	<212> PRT															
	<213> Homo sapiens															
55	<400> 77															

EP 2 850 097 B1

Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
1 5 10 15

5 Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val
20 25 30

<210> 78

<211> 15

10 <212> PRT

<213> Homo sapiens

<400> 78

15 Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro
1 5 10 15

<210> 79

<211> 14

20 <212> PRT

<213> Homo sapiens

<400> 79

25 Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile
1 5 10

<210> 80

<211> 13

30 <212> PRT

<213> Homo sapiens

<400> 80

35 Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe
1 5 10

<210> 81

<211> 12

40 <212> PRT

<213> Homo sapiens

<400> 81

45 Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg
1 5 10

<210> 82

<211> 11

50 <212> PRT

<213> Homo sapiens

<400> 82

55 Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu
1 5 10

<210> 83

EP 2 850 097 B1

<211> 10
 <212> PRT
 <213> Homo sapiens

5 <400> 83

Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg
 1 5 10

10 <210> 84
 <211> 9
 <212> PRT
 <213> Homo sapiens

15 <400> 84

Glu Ala Arg Pro Ala Leu Leu Thr Ser
 1 5

20 <210> 85
 <211> 8
 <212> PRT
 <213> Homo sapiens

25 <400> 85

Glu Ala Arg Pro Ala Leu Leu Thr
 1 5

30 <210> 86
 <211> 7
 <212> PRT
 <213> Homo sapiens

35 <400> 86

Glu Ala Arg Pro Ala Leu Leu
 1 5

40 <210> 87
 <211> 6
 <212> PRT
 <213> Homo sapiens

45 <400> 87

Glu Ala Arg Pro Ala Leu
 1 5

50 <210> 88
 <211> 5
 <212> PRT
 <213> Homo sapiens

55 <400> 88

Glu Ala Arg Pro Ala
 1 5

EP 2 850 097 B1

<210> 89
 <211> 4
 <212> PRT
 <213> Homo sapiens
 5
 <400> 89

 Glu Ala Arg Pro
 1
 10
 <210> 90
 <211> 3
 <212> PRT
 <213> Homo sapiens
 15
 <400> 90

 Glu Ala Arg
 1
 20
 <210> 91
 <211> 15
 <212> PRT
 <213> Homo sapiens
 25
 <400> 91

 Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
 1 5 10 15
 30
 <210> 92
 <211> 14
 <212> PRT
 <213> Homo sapiens
 35
 <400> 92

 Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
 1 5 10
 40
 <210> 93
 <211> 13
 <212> PRT
 <213> Homo sapiens
 45
 <400> 93

 Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
 1 5 10
 50
 <210> 94
 <211> 12
 <212> PRT
 <213> Homo sapiens
 55
 <400> 94

EP 2 850 097 B1

Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
1 5 10

5
<210> 95
<211> 11
<212> PRT
<213> Homo sapiens

10
<400> 95

Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys
1 5 10

15
<210> 96
<211> 10
<212> PRT
<213> Homo sapiens

20
<400> 96

Leu Thr Ser Arg Leu Arg Phe Ile Pro Lys

25 1 5 10

<210> 97
<211> 9
<212> PRT
30 <213> Homo sapiens

<400> 97

35 Thr Ser Arg Leu Arg Phe Ile Pro Lys
1 5

<210> 98
<211> 8
<212> PRT
40 <213> Homo sapiens

<400> 98

45 Ser Arg Leu Arg Phe Ile Pro Lys
1 5

<210> 99
<211> 7
<212> PRT
50 <213> Homo sapiens

<400> 99

55 Arg Leu Arg Phe Ile Pro Lys
1 5

<210> 100
<211> 6

EP 2 850 097 B1

<212> PRT
<213> Homo sapiens

<400> 100

5

Leu Arg Phe Ile Pro Lys
1 5

<210> 101
<211> 5
<212> PRT
<213> Homo sapiens

10

<400> 101

15

Arg Phe Ile Pro Lys
1 5

<210> 102
<211> 4
<212> PRT
<213> Homo sapiens

20

<400> 102

25

Phe Ile Pro Lys
1

<210> 103
<211> 3
<212> PRT
<213> Homo sapiens

30

<400> 103

35

Ile Pro Lys
1

<210> 104
<211> 14
<212> PRT
<213> Homo sapiens

40

<400> 104

45

Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro
1 5 10

<210> 105
<211> 12
<212> PRT
<213> Homo sapiens

50

<400> 105

55

Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile
1 5 10

EP 2 850 097 B1

<210> 106
 <211> 10
 <212> PRT
 <213> Homo sapiens
 5
 <400> 106

 Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe
 1 5 10
 10
 <210> 107
 <211> 8
 <212> PRT
 <213> Homo sapiens
 15
 <400> 107

 Ala Leu Leu Thr Ser Arg Leu Arg
 1 5
 20
 <210> 108
 <211> 6
 <212> PRT
 <213> Homo sapiens
 25
 <400> 108

 Leu Leu Thr Ser Arg Leu
 1 5
 30
 <210> 109
 <211> 4
 <212> PRT
 <213> Homo sapiens
 35
 <400> 109

 Leu Thr Ser Arg
 1
 40
 <210> 110
 <211> 13
 <212> PRT
 <213> Homo sapiens
 45
 <400> 110

 Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile
 1 5 10
 50
 <210> 111
 <211> 12
 <212> PRT
 <213> Homo sapiens
 55
 <400> 111

EP 2 850 097 B1

Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe
1 5 10

5 <210> 112
<211> 11
<212> PRT
<213> Homo sapiens

10 <400> 112

Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg
1 5 10

15 <210> 113
<211> 10
<212> PRT
<213> Homo sapiens

20 <400> 113

Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu
1 5 10

25 <210> 114
<211> 9
<212> PRT
<213> Homo sapiens

30 <400> 114

Ala Arg Pro Ala Leu Leu Thr Ser Arg
1 5

35 <210> 115
<211> 8
<212> PRT
<213> Homo sapiens

40 <400> 115

Ala Arg Pro Ala Leu Leu Thr Ser
1 5

45 <210> 116
<211> 7
<212> PRT
<213> Homo sapiens

50 <400> 116

Ala Arg Pro Ala Leu Leu Thr
1 5

55 <210> 117
<211> 6
<212> PRT
<213> Homo sapiens

EP 2 850 097 B1

<400> 117

Ala Arg Pro Ala Leu Leu
1 5

5

<210> 118
<211> 5
<212> PRT
<213> Homo sapiens

10

<400> 118

Ala Arg Pro Ala Leu
1 5

15

<210> 119
<211> 4
<212> PRT
<213> Homo sapiens

20

<400> 119

Ala Arg Pro Ala
1

25

<210> 120
<211> 3
<212> PRT
<213> Homo sapiens

30

<400> 120

Ala Arg Pro
1

35

<210> 121
<211> 13
<212> PRT
<213> Homo sapiens

40

<400> 121

Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro
1 5 10

45

<210> 122
<211> 11
<212> PRT
<213> Homo sapiens

50

<400> 122

Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe
1 5 10

55

<210> 123
<211> 10

EP 2 850 097 B1

<212> PRT
<213> Homo sapiens

<400> 123

5

Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg
1 5 10

<210> 124
<211> 8
<212> PRT
<213> Homo sapiens

10

<400> 124

15

Arg Pro Ala Leu Leu Thr Ser Arg
1 5

<210> 125
<211> 7
<212> PRT
<213> Homo sapiens

20

<400> 125

25

Arg Pro Ala Leu Leu Thr Ser
1 5

<210> 126
<211> 6
<212> PRT
<213> Homo sapiens

30

<400> 126

35

Arg Pro Ala Leu Leu Thr
1 5

<210> 127
<211> 5
<212> PRT
<213> Homo sapiens

40

<400> 127

45

Arg Pro Ala Leu Leu
1 5

<210> 128
<211> 4
<212> PRT
<213> Homo sapiens

50

<400> 128

55

Arg Pro Ala Leu
1

EP 2 850 097 B1

<210> 129
 <211> 3
 <212> PRT
 <213> Homo sapiens
 5
 <400> 129

 Arg Pro Ala
 1
 10
 <210> 130
 <211> 12
 <212> PRT
 <213> Homo sapiens
 15
 <400> 130

 Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro
 1 5 10
 20
 <210> 131
 <211> 11
 <212> PRT
 <213> Homo sapiens
 25
 <400> 131

 Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile
 1 5 10
 30
 <210> 132
 <211> 9
 <212> PRT
 <213> Homo sapiens
 35
 <400> 132

 Pro Ala Leu Leu Thr Ser Arg Leu Arg
 1 5
 40
 <210> 133
 <211> 8
 <212> PRT
 <213> Homo sapiens
 45
 <400> 133

 Pro Ala Leu Leu Thr Ser Arg Leu
 1 5
 50
 <210> 134
 <211> 7
 <212> PRT
 <213> Homo sapiens
 55
 <400> 134

EP 2 850 097 B1

Pro Ala Leu Leu Thr Ser Arg
1 5

5
<210> 135
<211> 6
<212> PRT
<213> Homo sapiens

10
<400> 135

Pro Ala Leu Leu Thr Ser
1 5

15
<210> 136
<211> 5
<212> PRT
<213> Homo sapiens

20
<400> 136

Pro Ala Leu Leu Thr
1 5

25
<210> 137
<211> 4
<212> PRT
<213> Homo sapiens

30
<400> 137

Pro Ala Leu Leu
1

35
<210> 138
<211> 3
<212> PRT
<213> Homo sapiens

40
<400> 138

Pro Ala Leu
1

45
<210> 139
<211> 11
<212> PRT
<213> Homo sapiens

50
<400> 139

Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro
1 5 10

55
<210> 140
<211> 9
<212> PRT
<213> Homo sapiens

EP 2 850 097 B1

<400> 140

Ala Leu Leu Thr Ser Arg Leu Arg Phe
1 5

5

<210> 141
<211> 7
<212> PRT
<213> Homo sapiens

10

<400> 141

Ala Leu Leu Thr Ser Arg Leu
1 5

15

<210> 142
<211> 6
<212> PRT
<213> Homo sapiens

20

<400> 142

Ala Leu Leu Thr Ser Arg
1 5

25

<210> 143
<211> 5
<212> PRT
<213> Homo sapiens

30

<400> 143

Ala Leu Leu Thr Ser
1 5

35

<210> 144
<211> 4
<212> PRT
<213> Homo sapiens

40

<400> 144

Ala Leu Leu Thr
1

45

<210> 145
<211> 3
<212> PRT
<213> Homo sapiens

50

<400> 145

Ala Leu Leu
1

55

<210> 146
<211> 10

EP 2 850 097 B1

<212> PRT
<213> Homo sapiens

<400> 146

5

Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro
1 5 10

<210> 147
<211> 9
<212> PRT
<213> Homo sapiens

10

<400> 147

15

Leu Leu Thr Ser Arg Leu Arg Phe Ile
1 5

<210> 148
<211> 8
<212> PRT
<213> Homo sapiens

20

<400> 148

25

Leu Leu Thr Ser Arg Leu Arg Phe
1 5

<210> 149
<211> 7
<212> PRT
<213> Homo sapiens

30

<400> 149

35

Leu Leu Thr Ser Arg Leu Arg
1 5

<210> 150
<211> 5
<212> PRT
<213> Homo sapiens

40

<400> 150

45

Leu Leu Thr Ser Arg
1 5

<210> 151
<211> 4
<212> PRT
<213> Homo sapiens

50

<400> 151

55

Leu Leu Thr Ser
1

EP 2 850 097 B1

<210> 152
 <211> 3
 <212> PRT
 <213> Homo sapiens
 5
 <400> 152

 Leu Leu Thr
 1
 10
 <210> 153
 <211> 9
 <212> PRT
 <213> Homo sapiens
 15
 <400> 153

 Leu Thr Ser Arg Leu Arg Phe Ile Pro
 1 5
 20
 <210> 154
 <211> 8
 <212> PRT
 <213> Homo sapiens
 25
 <400> 154

 Leu Thr Ser Arg Leu Arg Phe Ile
 1 5
 30
 <210> 155
 <211> 7
 <212> PRT
 <213> Homo sapiens
 35
 <400> 155

 Leu Thr Ser Arg Leu Arg Phe
 1 5
 40
 <210> 156
 <211> 6
 <212> PRT
 <213> Homo sapiens
 45
 <400> 156

 Leu Thr Ser Arg Leu Arg
 1 5
 50
 <210> 157
 <211> 5
 <212> PRT
 <213> Homo sapiens
 55
 <400> 157

EP 2 850 097 B1

Leu Thr Ser Arg Leu
1 5

5
<210> 158
<211> 3
<212> PRT
<213> Homo sapiens

10
<400> 158

Leu Thr Ser
1

15
<210> 159
<211> 8
<212> PRT
<213> Homo sapiens

20
<400> 159

Thr Ser Arg Leu Arg Phe Ile Pro

25 1 5

<210> 160
<211> 7
<212> PRT
30 <213> Homo sapiens

<400> 160

35 Thr Ser Arg Leu Arg Phe Ile
1 5

<210> 161
<211> 6
<212> PRT
40 <213> Homo sapiens

<400> 161

45 Thr Ser Arg Leu Arg Phe
1 5

<210> 162
<211> 5
<212> PRT
50 <213> Homo sapiens

<400> 162

55 Thr Ser Arg Leu Arg
1 5

<210> 163
<211> 4

EP 2 850 097 B1

<212> PRT
<213> Homo sapiens

<400> 163

5

Thr Ser Arg Leu
1

<210> 164
<211> 3
<212> PRT
<213> Homo sapiens

10

<400> 164

15

Thr Ser Arg
1

<210> 165
<211> 7
<212> PRT
<213> Homo sapiens

20

<400> 165

25

Ser Arg Leu Arg Phe Ile Pro
1 5

<210> 166
<211> 6
<212> PRT
<213> Homo sapiens

30

<400> 166

35

Ser Arg Leu Arg Phe Ile
1 5

<210> 167
<211> 5
<212> PRT
<213> Homo sapiens

40

<400> 167

45

Ser Arg Leu Arg Phe
1 5

<210> 168
<211> 4
<212> PRT
<213> Homo sapiens

50

<400> 168

55

Ser Arg Leu Arg
1

EP 2 850 097 B1

5
 <210> 169
 <211> 3
 <212> PRT
 <213> Homo sapiens

<400> 169

Ser Arg Leu
 1

10
 <210> 170
 <211> 6
 <212> PRT
 <213> Homo sapiens

15
 <400> 170

Arg Leu Arg Phe Ile Pro
 1 5

20
 <210> 171
 <211> 5
 <212> PRT
 <213> Homo sapiens

25
 <400> 171

Arg Leu Arg Phe Ile
 1 5

30
 <210> 172
 <211> 4
 <212> PRT
 <213> Homo sapiens

35
 <400> 172

Arg Leu Arg Phe
 1

40
 <210> 173
 <211> 3
 <212> PRT
 <213> Homo sapiens

45
 <400> 173

Arg Leu Arg
 1

50
 <210> 174
 <211> 5
 <212> PRT
 <213> Homo sapiens

55
 <400> 174

EP 2 850 097 B1

Leu Arg Phe Ile Pro
1 5

5 <210> 175
<211> 4
<212> PRT
<213> Homo sapiens

10 <400> 175

Leu Arg Phe Ile
1

15 <210> 176
<211> 3
<212> PRT
<213> Homo sapiens

20 <400> 176

Leu Arg Phe
1

25 <210> 177
<211> 4
<212> PRT
<213> Homo sapiens

30 <400> 177

Arg Phe Ile Pro
1

35 <210> 178
<211> 3
<212> PRT
<213> Homo sapiens

40 <400> 178

Arg Phe Ile
1

45 <210> 179
<211> 3
<212> PRT
<213> Homo sapiens

50 <400> 179

Phe Ile Pro
1

55 <210> 180
<211> 1132
<212> PRT
<213> Homo sapiens

EP 2 850 097 B1

<400> 180

5	Met	Pro	Arg	Ala	Pro	Arg	Cys	Arg	Ala	Val	Arg	Ser	Leu	Leu	Arg	Ser	1	5	10	15
	His	Tyr	Arg	Glu	Val	Leu	Pro	Leu	Ala	Thr	Phe	Val	Arg	Arg	Leu	Gly	20	25	30	
10	Pro	Gln	Gly	Trp	Arg	Leu	Val	Gln	Arg	Gly	Asp	Pro	Ala	Ala	Phe	Arg	35	40	45	
15	Ala	Leu	Val	Ala	Gln	Cys	Leu	Val	Cys	Val	Pro	Trp	Asp	Ala	Arg	Pro	50	55	60	
20	Pro	Pro	Ala	Ala	Pro	Ser	Phe	Arg	Gln	Val	Ser	Cys	Leu	Lys	Glu	Leu	65	70	75	80
	Val	Ala	Arg	Val	Leu	Gln	Arg	Leu	Cys	Glu	Arg	Gly	Ala	Lys	Asn	Val	85	90	95	

EP 2 850 097 B1

	Leu	Ala	Phe	Gly	Phe	Ala	Leu	Leu	Asp	Gly	Ala	Arg	Gly	Gly	Pro	Pro	
				100					105						110		
5	Glu	Ala	Phe	Thr	Thr	Ser	Val	Arg	Ser	Tyr	Leu	Pro	Asn	Thr	Val	Thr	
				115				120					125				
10	Asp	Ala	Leu	Arg	Gly	Ser	Gly	Ala	Trp	Gly	Leu	Leu	Leu	Arg	Arg	Val	
				130			135					140					
15	Gly	Asp	Asp	Val	Leu	Val	His	Leu	Leu	Ala	Arg	Cys	Ala	Leu	Phe	Val	
	145					150					155					160	
20	Leu	Val	Ala	Pro	Ser	Cys	Ala	Tyr	Gln	Val	Cys	Gly	Pro	Pro	Leu	Tyr	
					165					170					175		
25	Gln	Leu	Gly	Ala	Ala	Thr	Gln	Ala	Arg	Pro	Pro	Pro	His	Ala	Ser	Gly	
				180					185					190			
30	Pro	Arg	Arg	Arg	Leu	Gly	Cys	Glu	Arg	Ala	Trp	Asn	His	Ser	Val	Arg	
				195				200					205				
35	Glu	Ala	Gly	Val	Pro	Leu	Gly	Leu	Pro	Ala	Pro	Gly	Ala	Arg	Arg	Arg	
		210					215					220					
40	Gly	Gly	Ser	Ala	Ser	Arg	Ser	Leu	Pro	Leu	Pro	Lys	Arg	Pro	Arg	Arg	
	225					230					235					240	
45	Gly	Ala	Ala	Pro	Glu	Pro	Glu	Arg	Thr	Pro	Val	Gly	Gln	Gly	Ser	Trp	
					245					250					255		
50	Ala	His	Pro	Gly	Arg	Thr	Arg	Gly	Pro	Ser	Asp	Arg	Gly	Phe	Cys	Val	
				260					265					270			
55	Val	Ser	Pro	Ala	Arg	Pro	Ala	Glu	Glu	Ala	Thr	Ser	Leu	Glu	Gly	Ala	
				275				280					285				
60	Leu	Ser	Gly	Thr	Arg	His	Ser	His	Pro	Ser	Val	Gly	Arg	Gln	His	His	
		290					295					300					
65	Ala	Gly	Pro	Pro	Ser	Thr	Ser	Arg	Pro	Pro	Arg	Pro	Trp	Asp	Thr	Pro	
	305					310					315					320	
70	Cys	Pro	Pro	Val	Tyr	Ala	Glu	Thr	Lys	His	Phe	Leu	Tyr	Ser	Ser	Gly	
					325					330					335		
75	Asp	Lys	Glu	Gln	Leu	Arg	Pro	Ser	Phe	Leu	Leu	Ser	Ser	Leu	Arg	Pro	

EP 2 850 097 B1

	340		345		350
5	Ser Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly Ser	355	360	365	
10	Arg Pro Trp Met Pro Gly Thr Pro Arg Arg Leu Pro Arg Leu Pro Gln	370	375	380	
15	Arg Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn His	385	390	395	400
20	Ala Gln Cys Pro Tyr Gly Val Leu Leu Lys Thr His Cys Pro Leu Arg	405	410	415	
25	Ala Ala Val Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro Gln	420	425	430	
30	Gly Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg Leu	435	440	445	
35	Val Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly Phe	450	455	460	
40	Val Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly Ser	465	470	475	480
45	Arg His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile Ser	485	490	495	
50	Leu Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys Met	500	505	510	
55	Ser Val Arg Asp Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly Cys	515	520	525	
	Val Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys Phe	530	535	540	
	Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser Phe	545	550	555	560
	Phe Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Arg Leu Phe Phe Tyr	565	570	575	
	Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln His	580	585	590	

EP 2 850 097 B1

	Leu	Lys	Arg	Val	Gln	Leu	Arg	Glu	Leu	Ser	Glu	Ala	Glu	Val	Arg	Gln	
			595					600					605				
5	His	Arg	Glu	Ala	Arg	Pro	Ala	Leu	Leu	Thr	Ser	Arg	Leu	Arg	Phe	Ile	
			610				615					620					
10	Pro	Lys	Pro	Asp	Gly	Leu	Arg	Pro	Ile	Val	Asn	Met	Asp	Tyr	Val	Val	
			625			630					635					640	
	Gly	Ala	Arg	Thr	Phe	Arg	Arg	Glu	Lys	Arg	Ala	Glu	Arg	Leu	Thr	Ser	
					645					650					655		
15	Arg	Val	Lys	Ala	Leu	Phe	Ser	Val	Leu	Asn	Tyr	Glu	Arg	Ala	Arg	Arg	
				660					665					670			
20	Pro	Gly	Leu	Leu	Gly	Ala	Ser	Val	Leu	Gly	Leu	Asp	Asp	Ile	His	Arg	
			675					680					685				
25	Ala	Trp	Arg	Thr	Phe	Val	Leu	Arg	Val	Arg	Ala	Gln	Asp	Pro	Pro	Pro	
		690					695					700					
	Glu	Leu	Tyr	Phe	Val	Lys	Val	Asp	Val	Thr	Gly	Ala	Tyr	Asp	Thr	Ile	
		705				710					715					720	
30	Pro	Gln	Asp	Arg	Leu	Thr	Glu	Val	Ile	Ala	Ser	Ile	Ile	Lys	Pro	Gln	
					725					730					735		
35	Asn	Thr	Tyr	Cys	Val	Arg	Arg	Tyr	Ala	Val	Val	Gln	Lys	Ala	Ala	His	
				740					745					750			
40	Gly	His	Val	Arg	Lys	Ala	Phe	Lys	Ser	His	Val	Ser	Thr	Leu	Thr	Asp	
			755					760					765				
	Leu	Gln	Pro	Tyr	Met	Arg	Gln	Phe	Val	Ala	His	Leu	Gln	Glu	Thr	Ser	
		770					775					780					
45	Pro	Leu	Arg	Asp	Ala	Val	Val	Ile	Glu	Gln	Ser	Ser	Ser	Leu	Asn	Glu	
		785				790					795					800	
50	Ala	Ser	Ser	Gly	Leu	Phe	Asp	Val	Phe	Leu	Arg	Phe	Met	Cys	His	His	
				805					810					815			
	Ala	Val	Arg	Ile	Arg	Gly	Lys	Ser	Tyr	Val	Gln	Cys	Gln	Gly	Ile	Pro	
				820					825					830			
55	Gln	Gly	Ser	Ile	Leu	Ser	Thr	Leu	Leu	Cys	Ser	Leu	Cys	Tyr	Gly	Asp	
			835					840					845				

EP 2 850 097 B1

	Met	Glu	Asn	Lys	Leu	Phe	Ala	Gly	Ile	Arg	Arg	Asp	Gly	Leu	Leu	Leu	
	850						855					860					
5	Arg	Leu	Val	Asp	Asp	Phe	Leu	Leu	Val	Thr	Pro	His	Leu	Thr	His	Ala	
	865					870					875					880	
10	Lys	Thr	Phe	Leu	Arg	Thr	Leu	Val	Arg	Gly	Val	Pro	Glu	Tyr	Gly	Cys	
					885					890					895		
15	Val	Val	Asn	Leu	Arg	Lys	Thr	Val	Val	Asn	Phe	Pro	Val	Glu	Asp	Glu	
				900					905					910			
20	Ala	Leu	Gly	Gly	Thr	Ala	Phe	Val	Gln	Met	Pro	Ala	His	Gly	Leu	Phe	
			915					920					925				
25	Pro	Trp	Cys	Gly	Leu	Leu	Leu	Asp	Thr	Arg	Thr	Leu	Glu	Val	Gln	Ser	
	930						935					940					
30	Asp	Tyr	Ser	Ser	Tyr	Ala	Arg	Thr	Ser	Ile	Arg	Ala	Ser	Leu	Thr	Phe	
	945					950					955					960	
35	Asn	Arg	Gly	Phe	Lys	Ala	Gly	Arg	Asn	Met	Arg	Arg	Lys	Leu	Phe	Gly	
					965					970					975		
40	Val	Leu	Arg	Leu	Lys	Cys	His	Ser	Leu	Phe	Leu	Asp	Leu	Gln	Val	Asn	
				980					985					990			
45	Ser	Leu	Gln	Thr	Val	Cys	Thr	Asn	Ile	Tyr	Lys	Ile	Leu	Leu	Leu	Gln	
			995					1000					1005				
50	Ala	Tyr	Arg	Phe	His	Ala	Cys	Val	Leu	Gln	Leu	Pro	Phe	His	Gln		
	1010						1015					1020					
55	Gln	Val	Trp	Lys	Asn	Pro	Thr	Phe	Phe	Leu	Arg	Val	Ile	Ser	Asp		
	1025						1030					1035					
60	Thr	Ala	Ser	Leu	Cys	Tyr	Ser	Ile	Leu	Lys	Ala	Lys	Asn	Ala	Gly		
	1040						1045					1050					
65	Met	Ser	Leu	Gly	Ala	Lys	Gly	Ala	Ala	Gly	Pro	Leu	Pro	Ser	Glu		
	1055						1060					1065					
70	Ala	Val	Gln	Trp	Leu	Cys	His	Gln	Ala	Phe	Leu	Leu	Lys	Leu	Thr		
	1070						1075					1080					
75	Arg	His	Arg	Val	Thr	Tyr	Val	Pro	Leu	Leu	Gly	Ser	Leu	Arg	Thr		
	1085						1090					1095					

Ala Gln Thr Gln Leu Ser Arg Lys Leu Pro Gly Thr Thr Leu Thr
 1100 1105 1110

Ala Leu Glu Ala Ala Ala Asn Pro Ala Leu Pro Ser Asp Phe Lys
 1115 1120 1125

Thr Ile Leu Asp
 1130

Claims

1. A peptide with anti-inflammatory activity, wherein the peptide is selected from the group consisting of SEQ ID NO: 116, 117 and 118.
2. The peptide according to claim 1, wherein the peptide originates from human telomerase.
3. The peptide according to claim 1 or 2, for use as a medicament.
4. The peptide according to claim 1 or 2 for use in treatment or prophylaxis of inflammatory disease.
5. A polynucleotide encoding a peptide selected from the group consisting of: SEQ ID NO: 116, 117, and 118.
6. An anti-inflammatory composition comprising a peptide selected from the group consisting of SEQ ID NO: 116, 117, and 118 as an active ingredient.
7. The anti-inflammatory composition according to claim 6 for use in the treatment or prophylaxis of an inflammatory disease, wherein the composition is a pharmaceutical composition.
8. The anti-inflammatory composition according to claim 6 for use in improving or preventing skin inflammation, wherein the composition is a cosmetic composition.
9. The anti-inflammatory composition according to claim 6 for use in the treatment or prophylaxis of inflammation, wherein the composition is a food composition.
10. The anti-inflammatory composition for the use according to claim 7, wherein the inflammatory disease is selected from the group consisting of (1) general or localized inflammatory disease (for example, allergies; immune-complex disease; hayfever; hypersensitive shock; endotoxin shock; cachexia, hyperthermia; granulomatosis; or sarcoidosis); (2) gastro-intestinal related diseases (for example, appendicitis; gastric ulcer; duodenal ulcer; peritonitis; pancreatitis; ulcerative, acute, or ischemic colitis; cholangitis; cholecystitis; steatorrhea, hepatitis, Crohn's disease; or Whipple's Disease); (3) dermal related diseases (for example, psoriasis; burns; sunburns; dermatitis; Urticarial warts or wheal); (4) vascular related diseases (for example, angiitis; vasculitis; endocarditis; arteritis; atherosclerosis; thrombophlebitis; pericarditis; congestive heart failure; myocarditis; myocardial ischemia; periarteritis nodosa; recurrent stenosis; Buerger's disease; or rheumatic fever); (5) respiratory diseases (for example, asthma; epiglottitis; bronchitis; emphysema; rhinitis; cystic fibrosis; interstitial pneumonitis; COPD(chronic obstructive pulmonary disease); adult respiratory distress syndrome; coniosis; alveolitis; bronchiolitis; pharyngitis; pleurisy; or sinusitis); (6) bone, joint, muscle and connective tissue related diseases (for example, eosinophilic granuloma; arthritis; arthralgia; osteomyelitis; dermatomyositis; fasciitis; Paget's disease; gout; periodontal disease; rheumatoid arthritis; myasthenia gravis; ankylosing spondylitis; or synovitis); (7) urogenital disorders (for example, epididymitis; vaginitis; prostatitis; or urethritis); (8) central or peripheral nervous system related diseases (for example, Alzheimer's disease; meningitis; encephalitis; multiple sclerosis; cerebral infarction; cerebral embolism; Guillain-Barre syndrome; neuritis; neuralgia; spinal cord injury; paralysis; or uveitis); (9) virus (for example, influenza; respiratory syncytial virus; HIV; hepatitis B; hepatitis C; or herpes virus), infectious disease (for example, Dengue fever; or septicemia), fungal infection (for example, candidiasis); or bacterial, parasitic, and similar microbial infection (for example, disseminated bacteremia; malaria; onchocerciasis; or amebiasis); (10) autoimmune disease (for example, thyroiditis; lupus; Goodpasture's syndrome; allograft rejection; graft versus host disease; or diabetes); and (11) cancer or tumor disease (for example,

Hodgkin's disease).

11. A kit for prophylaxis or treatment of inflammatory diseases comprising: a peptide selected from the group consisting of SEQ ID NO: 116, 117 and 118, and instructions including at least one of administration dose, administration route, administration frequency, and indication of the peptide or composition.

Patentansprüche

1. Peptid mit entzündungshemmender Aktivität, wobei das Peptid ausgewählt wird aus der Gruppe bestehend aus SEQ ID NO: 116, 117 und 118.
2. Peptid nach Anspruch 1, wobei das Peptid aus menschlicher Telomerase stammt.
3. Peptid nach Anspruch 1 oder 2 zur Verwendung als Medikament.
4. Peptid nach Anspruch 1 oder 2 zur Verwendung bei der Behandlung oder Prophylaxe von Entzündungserkrankungen.
5. Polynukleotid, das ein Peptid codiert, das aus der Gruppe bestehend aus SEQ ID NO: 116, 117 und 118 besteht.
6. Entzündungshemmende Zusammensetzung, die ein Peptid enthält, das aus der Gruppe bestehend aus SEQ ID NO: 116, 117 und 118 als Wirkstoff besteht.
7. Entzündungshemmende Zusammensetzung nach Anspruch 6 zur Verwendung bei der Behandlung oder Prophylaxe einer Entzündungserkrankung, wobei die Zusammensetzung eine pharmazeutische Zusammensetzung ist.
8. Entzündungshemmende Zusammensetzung nach Anspruch 6 zur Verwendung bei der Verbesserung oder Verhütung von Hautentzündung, wobei die Zusammensetzung eine kosmetische Zusammensetzung ist.
9. Entzündungshemmende Zusammensetzung nach Anspruch 6 zur Verwendung bei der Behandlung oder Prophylaxe einer Entzündung, wobei die Zusammensetzung eine Nahrungszusammensetzung ist.
10. Entzündungshemmende Zusammensetzung zur Verwendung nach Anspruch 7, wobei die Entzündungserkrankung ausgewählt wird aus der Gruppe bestehend aus (1) allgemeiner oder lokalisierter Entzündungserkrankung (zum Beispiel Allergien; Immunkomplexerkrankung; Heuschnupfen; hypersensitiver Schock; Endotoxinschock; Kachexie, Hyperthermie; Granulomatose oder Sarkoidose); (2) gastrointestinal-bezogene Krankheiten (zum Beispiel Appendizitis; Magengeschwür; Duodenalulkus; Peritonitis; Pankreatitis; ulzerative, akute oder ischämische Colitis; Cholangitis; Cholecystitis, Steatorrhoe, Hepatitis, Crohn-Krankheit oder Whipple-Krankheit); (3) hautbezogene Krankheiten (zum Beispiel Psoriasis; Verbrennungen; Sonnenbrände; Dermatitis; Urticaria-Warzen oder Quaddelbildung); (4) gefäßbezogene Krankheiten (zum Beispiel Angiitis; Vaskulitis; Endokarditis; Arteritis; Atherosklerose; Thrombophlebitis; Perikarditis; kongestives Herzversagen; Myokarditis; Myokardischämie; Periarteritis nodosa; rezidivierende Stenose; Buerger-Erkrankung oder rheumatisches Fieber); (5) respiratorische Erkrankungen (zum Beispiel Asthma; Epiglottitis; Bronchitis; Emphysem; Rhinitis; zystische Fibrose; interstitielle Pneumonitis; COPD (chronische obstruktive Lungenerkrankung); Atemnotsyndrom bei Erwachsenen; Koniose; Alveolitis; Bronchiolitis; Pharyngitis; Pleuritis oder Sinusitis); (6) Knochen-, Gelenk-, Muskel- und bindegewebsbezogene Krankheiten (zum Beispiel eosinophiles Granulom; Arthritis; Arthralgie; Osteomyelitis; Dermatomyositis; Faszitis; Paget-Erkrankung; Gicht; Parodontose; rheumatoide Arthritis; Myasthenia gravis; ankylosierende Spondylitis oder Synovitis); (7) urogenitale Erkrankungen (zum Beispiel Epididymitis; Vaginitis; Prostatitis oder Urethritis); (8) Zentral- oder Peripher-Nervensystem-bezogene Krankheiten (zum Beispiel Alzheimer-Krankheit; Meningitis; Encephalitis; multiple Sklerose; Hirninfarkt; Hirnembolie; Guillain-Barre-Syndrom; Neuritis; Neuralgie; Rückenmarksverletzung; Paralyse oder Uveitis); (9) Viruserkrankungen (zum Beispiel Influenza; respiratorisches Synzytialvirus; HIV; Hepatitis B; Hepatitis C oder Herpes-Virus), Infektionskrankheit (zum Beispiel Dengue-Fieber; oder Septikämie), Pilzerkrankung (zum Beispiel Candidiasis); oder bakterielle, parasitische und ähnliche mikrobielle Infektion (zum Beispiel disseminierte Bakteriämie; Malaria; Onchozerkose oder Amöbiasis); (10) Autoimmunerkrankung (zum Beispiel Thyroiditis; Lupus; Goodpasture-Syndrom; Allotransplantatabstoßung; Graft-versus-Host-Reaktion oder Diabetes); und (11) Krebs oder Tumorerkrankung (zum Beispiel Hodgkin-Krankheit).

11. Kit zur Prophylaxe oder Behandlung von Entzündungskrankheiten, umfassend: ein Peptid, das aus der Gruppe bestehend aus SEQ ID NO: 116, 117 und 118 ausgewählt wird, und Anweisungen, die zumindest ein Element aus Verabreichungsdosis, Verabreichungsweg, Verabreichungshäufigkeit und Indikation für das Peptid oder die Zusammensetzung enthalten.

5

Revendications

1. Peptide ayant une activité anti-inflammatoire, dans lequel le peptide est sélectionné dans le groupe constitué de SEQ ID NO : 116, 117 et 118.
2. Peptide selon la revendication 1, dans lequel le peptide provient de la télomérase humaine.
3. Peptide selon la revendication 1 ou 2, pour son utilisation en tant que médicament.
4. Peptide selon la revendication 1 ou 2, pour son utilisation dans le traitement ou la prophylaxie d'une maladie inflammatoire.
5. Polynucléotide codant pour un peptide sélectionné dans le groupe constitué de SEQ ID NO : 116, 117 et 118.
6. Composition anti-inflammatoire comprenant un peptide sélectionné dans le groupe constitué de SEQ ID NO : 116, 117 et 118 en tant que principe actif.
7. Composition anti-inflammatoire selon la revendication 6, pour son utilisation dans le traitement ou la prophylaxie d'une maladie inflammatoire, dans laquelle la composition est une composition pharmaceutique.
8. Composition anti-inflammatoire selon la revendication 6, pour son utilisation dans l'amélioration ou la prévention d'une inflammation cutanée, dans laquelle la composition est une composition cosmétique.
9. Composition anti-inflammatoire selon la revendication 6, pour son utilisation dans le traitement ou la prophylaxie d'une inflammation, dans laquelle la composition est une composition alimentaire.
10. Composition anti-inflammatoire pour son utilisation selon la revendication 7, dans laquelle la maladie inflammatoire est sélectionnée dans le groupe constitué (1) d'une maladie inflammatoire générale ou localisée (par exemple, des allergies ; une maladie à complexes immuns ; le rhume des foins ; un choc hypersensible ; un choc endotoxinique ; la cachexie, l'hyperthermie ; la granulomatose ; ou la sarcoïdose) ; (2) de maladies associées au tractus gastro-intestinal (par exemple, l'appendicite ; un ulcère gastrique ; un ulcère duodénal ; une péritonite ; une pancréatite ; une rectocolite hémorragique, aiguë ou ischémique ; une cholangite ; une cholécystite ; une stéatorrhée, une hépatite, la maladie de Crohn ; ou la maladie de Whipple) ; (3) de maladies associées au derme (par exemple, le psoriasis ; des brûlures ; des coups de soleil ; une dermatite ; des verrues ou papules oedémateuses urticariennes) ; (4) de maladies associées au système vasculaire (par exemple, une angéite ; une vasculite ; une endocardite ; une artérite ; l'athérosclérose ; une thrombophlébite ; une péricardite ; une insuffisance cardiaque congestive ; une myocardite ; une ischémie du myocarde ; une périarthrite noueuse ; une sténose récurrente ; la maladie de Buerger ; ou un rhumatisme articulaire aigu) ; (5) de maladies respiratoires (par exemple, l'asthme ; une épiglottite ; une bronchite ; un emphysème ; une rhinite ; la mucoviscidose ; une pneumonite interstitielle ; une BPCO (bronchopneumopathie chronique obstructive) ; le syndrome de détresse respiratoire adulte ; une coniose ; une alvéolite ; une bronchiolite ; une pharyngite ; une pleurésie ; ou une sinusite) ; (6) de maladies liées aux tissus osseux, articulaire, musculaire et conjonctif (par exemple, un granulome éosinophile ; l'arthrite ; une arthralgie ; une ostéomyélite ; une dermatomyosite ; une fasciite ; la maladie de Paget ; la goutte ; une parodontopathie ; la polyarthrite rhumatoïde ; la myasthénie grave ; la spondylarthrite ankylosante ; ou une synovite) ; (7) de troubles urogénitaux (par exemple, une épидидymite ; une vaginite ; une prostatite ; ou une urétrite) ; (8) de maladies liées au système nerveux central ou périphérique (par exemple, la maladie d'Alzheimer ; une méningite ; une encéphalite ; la sclérose en plaques ; un infarctus cérébral ; un embolisme cérébral ; le syndrome de Guillain-Barré ; une névrite ; une névralgie ; une lésion de la moelle épinière ; une paralysie ; ou une uvéite) ; (9) d'un virus (par exemple, la grippe ; le virus respiratoire syncytial ; le VIH ; l'hépatite B ; l'hépatite C ; ou le virus de l'herpès), une maladie infectieuse (par exemple, la dengue ; ou une septicémie), une infection fongique (par exemple, la candidose) ; ou une infection bactérienne, parasitaire, et microbienne similaire (par exemple, une bactériémie disséminée ; le paludisme ; une onchocercose ; ou une amibiase) ; (10) d'une maladie auto-immune (par exemple, une thyroïdite ;

EP 2 850 097 B1

le lupus ; le syndrome de Goodpasture ; un rejet d'allogreffe ; la maladie du greffon contre l'hôte ; ou le diabète) ; et (11) une maladie cancéreuse ou tumorale (par exemple, la maladie de Hodgkin).

- 5 **11.** Kit pour la prophylaxie ou le traitement de maladies inflammatoires comprenant : un peptide sélectionné dans le groupe constitué de SEQ ID NO : 116, 117 et 118, et des instructions comprenant au moins l'une de la dose à administrer, de la voie d'administration, de la fréquence d'administration, et d'une indication du peptide ou de la composition.

10

15

20

25

30

35

40

45

50

55

FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9





FIG. 10

FIG. 11




FIG. 12




FIG. 13




FIG. 14




FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 25




FIG. 26




FIG. 27





FIG. 28

FIG. 29




FIG. 30




FIG. 31




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36




FIG. 37





FIG. 38

FIG. 39




FIG. 40




FIG. 41




FIG. 42




FIG. 43




FIG. 44




FIG. 45




FIG.46




FIG.47





FIG.48

FIG.49





FIG.50

FIG.51




FIG.52




FIG.53




FIG.54




FIG.55




FIG.56









FIG.57

(A)

	Control	20 μ M A β	20 μ M A β + 1 μ M PEP1	20 μ M A β + 10 μ M PEP1	20 μ M A β + 50 μ M PEP1
CBB Image					
Total Spots	564	492	334	432	536





FIG.58






Fig. 58 cont.

FIG.59




FIG. 60




FIG. 61




FIG. 62




FIG. 63




FIG. 64




FIG. 65




FIG. 66




FIG. 67




FIG. 68




FIG. 69




FIG. 70




FIG. 71




FIG. 72




FIG. 73




FIG. 74




FIG. 75




FIG. 76




FIG. 77




FIG. 78




FIG. 79




FIG. 80




FIG. 81




FIG. 82




FIG. 83




FIG. 84




FIG. 85




FIG. 86




FIG. 87




FIG. 88




FIG. 89




FIG. 90




FIG. 91




FIG. 92




FIG. 93




FIG. 94




FIG. 95




FIG. 96




FIG. 97




FIG. 98




FIG. 99




FIG. 100




FIG. 101




FIG. 102




FIG. 103




FIG. 104




FIG. 105




FIG. 106




FIG. 107




FIG. 108




FIG. 109




FIG. 110




FIG. 111




FIG. 112




FIG. 113




FIG. 114




FIG. 115




FIG. 116




FIG. 117




FIG. 118




FIG. 119




FIG. 120




FIG. 121




FIG. 122




FIG. 123




FIG. 124




FIG. 125




FIG. 126




FIG. 127




FIG. 128




FIG. 129




FIG. 130




FIG. 131




FIG. 132




FIG. 133




FIG. 134




FIG. 135




FIG. 136




FIG. 137




FIG. 138




FIG. 139




FIG. 140




FIG. 141




FIG. 142




FIG. 143




FIG. 144




FIG. 145




FIG. 146




FIG. 147




FIG. 148




FIG. 149




FIG. 150




FIG. 151




FIG. 152




FIG. 153




FIG. 154




FIG. 155




FIG. 156




FIG. 157




FIG. 158





FIG. 159



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 0002581 A [0015]
- WO 2011101173 A [0016]
- US 2007190561 A [0017]
- KR 20120130996 A [0031]
- KR 20120133661 A [0031]
- KR 20110060940 A [0031] [0078]
- US 20110150873 A1 [0031]
- KR 1020120050529 [0138]
- KR 1020120050533 [0138]
- KR 1020120071989 [0138]
- KR 1020120104144 [0138]
- KR 1020120104207 [0138]

Non-patent literature cited in the description

- **MARTINEZ P et al.** *Nature Reviews Cancer*, 2011, vol. 11 (3), 161-176 [0018]
- **BONALDI T et al.** *EMBO J*, 2003, vol. 22, 5551-60 [0031] [0080]
- **YANKNER BA et al.** *Science*, 1990, vol. 250 (4978), 279-282 [0031]
- **DAHLGREN KN et al.** *J. Biol. Chem.*, 2002, vol. 277, 32046-32053 [0031]
- **SMITH ; WATERMAN.** *Adv. Appl. Math.*, 1981, vol. 2, 482 [0041]
- **PEARSON ; LIPMAN.** *Proc. Natl. Acad. Sci. USA*, 1988, vol. 85, 2444 [0041]
- **THOMPSON et al.** *Nucleic Acids Res*, 1994, vol. 22, 467380 [0041]
- **ALTSCHUL et al.** *Mol. Biol.*, 1990, vol. 215, 403-10 [0041]